{"FP": [{"generated": ["complete normalization", "progressive mobilization"], "gold": [], "text": "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings."}, {"generated": ["complete normalization", "progressive mobilization"], "gold": [], "text": "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings."}, {"generated": ["fourth course"], "gold": [], "text": "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event."}, {"generated": ["May 2009"], "gold": [], "text": "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection."}, {"generated": ["16"], "gold": [], "text": "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space."}, {"generated": ["not specified"], "gold": [], "text": "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin."}, {"generated": ["increased number and types of chemotherapeutic drugs", "prolonged life expectancy"], "gold": [], "text": "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8]."}, {"generated": ["increased number and types of chemotherapeutic drugs", "prolonged life expectancy"], "gold": [], "text": "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8]."}, {"generated": ["patient"], "gold": [], "text": "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms."}, {"generated": ["health risks", "complexity"], "gold": [], "text": "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use."}, {"generated": ["health risks", "complexity"], "gold": [], "text": "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use."}, {"generated": ["chronic back pain"], "gold": [], "text": "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes."}, {"generated": ["movement control", "low dopamine concentrations"], "gold": [], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": ["movement control", "low dopamine concentrations"], "gold": [], "text": "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8]."}, {"generated": ["pharmacodynamic", "pharmacokinetic", "pharmacogenomic"], "gold": [], "text": "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events."}, {"generated": ["pharmacodynamic", "pharmacokinetic", "pharmacogenomic"], "gold": [], "text": "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events."}, {"generated": ["pharmacodynamic", "pharmacokinetic", "pharmacogenomic"], "gold": [], "text": "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events."}, {"generated": ["past medical history", "chronic neck, back, and shoulder pain"], "gold": [], "text": "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain."}, {"generated": ["past medical history", "chronic neck, back, and shoulder pain"], "gold": [], "text": "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain."}, {"generated": ["early in the morning"], "gold": [], "text": "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1)."}, {"generated": ["additional medication"], "gold": [], "text": "However, his PCP determined that additional medication for pain control was warranted."}, {"generated": ["numerous ages found in text"], "gold": [], "text": "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21]."}, {"generated": ["no ages found in text"], "gold": [], "text": "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25]."}, {"generated": ["genotype for COMT Met/Met", "patient\u2019s PGx results (Table 1)"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["genotype for COMT Met/Met", "patient\u2019s PGx results (Table 1)"], "gold": [], "text": "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected."}, {"generated": ["one out of five"], "gold": [], "text": "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12]."}, {"generated": ["past two decades"], "gold": [], "text": "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment."}, {"generated": ["2009-2010"], "gold": [], "text": "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4]."}, {"generated": ["South Korean population", "29%", "83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["South Korean population", "29%", "83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["South Korean population", "29%", "83%"], "gold": [], "text": "In South Korean population reported a range from 29% to 83% [5]."}, {"generated": ["very narrow therapeutic indices"], "gold": [], "text": "An important fact is that most of these affected drugs have very narrow therapeutic indices."}, {"generated": ["an increasing number of studies"], "gold": [], "text": "To date an increasing number of studies in evaluating HDIs have been reported [11]."}, {"generated": ["clinic", "studies", "important"], "gold": [], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": ["clinic", "studies", "important"], "gold": [], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": ["clinic", "studies", "important"], "gold": [], "text": "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs."}, {"generated": ["rs1142345"], "gold": [], "text": "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs."}, {"generated": ["last decade"], "gold": [], "text": "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2]."}, {"generated": ["about 70%"], "gold": [], "text": "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14]."}, {"generated": ["potential interaction", "CYP2C19", "CYP2C9", "CYP1A2"], "gold": [], "text": "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities."}, {"generated": ["potential interaction", "CYP2C19", "CYP2C9", "CYP1A2"], "gold": [], "text": "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities."}, {"generated": ["potential interaction", "CYP2C19", "CYP2C9", "CYP1A2"], "gold": [], "text": "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities."}, {"generated": ["potential interaction", "CYP2C19", "CYP2C9", "CYP1A2"], "gold": [], "text": "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities."}, {"generated": ["time course", "metabolites", "K A", "non-targeted approach"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["time course", "metabolites", "K A", "non-targeted approach"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["time course", "metabolites", "K A", "non-targeted approach"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["time course", "metabolites", "K A", "non-targeted approach"], "gold": [], "text": "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "weight extracted powdered material", "weight of original starting material", "bioavailability", "plasma concentration"], "gold": [], "text": "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract."}, {"generated": ["tremendous surge", "public interest"], "gold": [], "text": "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI."}, {"generated": ["tremendous surge", "public interest"], "gold": [], "text": "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI."}, {"generated": ["chronically"], "gold": [], "text": "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier."}, {"generated": ["indigenous mode of extraction"], "gold": [], "text": "Extraction was performed using water to mimic the indigenous mode of extraction."}, {"generated": ["44"], "gold": [], "text": "[44]."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["vacuum degasser", "Waters micromass", "serial dilutions", "binary pump", "column oven", "Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)", "autosampler", "mixture of regeneration system", "UPLC system", "Acquity BEH C18 column"], "gold": [], "text": "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe."}, {"generated": ["almost all"], "gold": [], "text": "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug."}, {"generated": ["vivo", "clinical pharmacokinetic profile"], "gold": [], "text": "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly."}, {"generated": ["vivo", "clinical pharmacokinetic profile"], "gold": [], "text": "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly."}, {"generated": ["increasing"], "gold": [], "text": "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community."}, {"generated": ["31%"], "gold": [], "text": "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001)."}, {"generated": ["96 h after dose", "1985", "1, 20, 6, 14%"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["96 h after dose", "1985", "1, 20, 6, 14%"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["96 h after dose", "1985", "1, 20, 6, 14%"], "gold": [], "text": "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985)."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Elliot et al."}, {"generated": ["day before", "2 days after"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["day before", "2 days after"], "gold": [], "text": "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide."}, {"generated": ["2003"], "gold": [], "text": "(2003)."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Park et al."}, {"generated": ["1 : 40", "1 : 80"], "gold": [], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": ["1 : 40", "1 : 80"], "gold": [], "text": "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80."}, {"generated": ["mild cholangiolar proliferation", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "chronic hepatitis"], "gold": [], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["mild cholangiolar proliferation", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "chronic hepatitis"], "gold": [], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["mild cholangiolar proliferation", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "chronic hepatitis"], "gold": [], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["mild cholangiolar proliferation", "moderate plasma cell rich interface hepatitis", "periportal hepatocyte apoptosis", "chronic hepatitis"], "gold": [], "text": "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b))."}, {"generated": ["Tables 1, 2, and 3", "Case 1", "clinicopathological features"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["Tables 1, 2, and 3", "Case 1", "clinicopathological features"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["Tables 1, 2, and 3", "Case 1", "clinicopathological features"], "gold": [], "text": "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "initially asymptomatic", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "initially asymptomatic", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "initially asymptomatic", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["right upper quadrant abdominal pain", "lower extremity edema", "initially asymptomatic", "fatigue"], "gold": [], "text": "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation."}, {"generated": ["vasomotor symptoms of menopause"], "gold": [], "text": "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15]."}, {"generated": ["discontinuation of the herbal supplement"], "gold": [], "text": "This case culminated in liver failure despite discontinuation of the herbal supplement [4]."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["immune mechanism", "immunogen", "metabolite", "autoimmune response", "drug", "hapten", "host cellular protein"], "gold": [], "text": "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response."}, {"generated": ["Adults"], "gold": [], "text": "Naranjo [8] Causality Scale for Adverse Drug Reactions."}, {"generated": ["black cohosh hepatotoxicity", "case studies", "similarities", "differences", "published cases"], "gold": [], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["black cohosh hepatotoxicity", "case studies", "similarities", "differences", "published cases"], "gold": [], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["black cohosh hepatotoxicity", "case studies", "similarities", "differences", "published cases"], "gold": [], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["black cohosh hepatotoxicity", "case studies", "similarities", "differences", "published cases"], "gold": [], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["black cohosh hepatotoxicity", "case studies", "similarities", "differences", "published cases"], "gold": [], "text": "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity."}, {"generated": ["third-generation fluoroquinolone antibiotic family"], "gold": [], "text": "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8]."}, {"generated": ["urinary system infection"], "gold": [], "text": "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX."}, {"generated": ["in vivo distribution studies", "pharmacokinetic features"], "gold": [], "text": "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22]."}, {"generated": ["in vivo distribution studies", "pharmacokinetic features"], "gold": [], "text": "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22]."}, {"generated": ["rat tissue homogenate"], "gold": [], "text": "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate."}, {"generated": ["42 mg kg"], "gold": [], "text": "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD)."}, {"generated": ["acceptable limit", "\u00b115%"], "gold": [], "text": "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%."}, {"generated": ["acceptable limit", "\u00b115%"], "gold": [], "text": "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%."}, {"generated": ["entrance of LVFX", "distribution rate in the tissue"], "gold": [], "text": "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue."}, {"generated": ["entrance of LVFX", "distribution rate in the tissue"], "gold": [], "text": "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue."}, {"generated": ["pharmacodynamic interactions", "pharmacokinetic interactions"], "gold": [], "text": "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions."}, {"generated": ["pharmacodynamic interactions", "pharmacokinetic interactions"], "gold": [], "text": "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions."}, {"generated": ["2017"], "gold": [], "text": "KY[2017]073)."}, {"generated": ["people with diabetes"], "gold": [], "text": "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy."}, {"generated": ["antioxidant", "anti-inflammatory", "anticancer", "anti-osteoporosis"], "gold": [], "text": "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013)."}, {"generated": ["antioxidant", "anti-inflammatory", "anticancer", "anti-osteoporosis"], "gold": [], "text": "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013)."}, {"generated": ["antioxidant", "anti-inflammatory", "anticancer", "anti-osteoporosis"], "gold": [], "text": "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013)."}, {"generated": ["antioxidant", "anti-inflammatory", "anticancer", "anti-osteoporosis"], "gold": [], "text": "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["Penicillin-streptomycin", "Sodium Pyruvate", "Minimal Essential Medium (MEM)", "Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA"], "gold": [], "text": "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA)."}, {"generated": ["No ages found in text"], "gold": [], "text": "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates."}, {"generated": ["2011"], "gold": [], "text": "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011)."}, {"generated": ["2006"], "gold": [], "text": "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006)."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests."}, {"generated": ["hypoglycemic drugs", "hypocholesterolemic drugs"], "gold": [], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": ["hypoglycemic drugs", "hypocholesterolemic drugs"], "gold": [], "text": "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin."}, {"generated": ["global increase in the prevalence of diabetes and obesity"], "gold": [], "text": "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17]."}, {"generated": ["CYP2C9", "CYP3A4", "CYP2C8"], "gold": [], "text": "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4."}, {"generated": ["CYP2C9", "CYP3A4", "CYP2C8"], "gold": [], "text": "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4."}, {"generated": ["CYP2C9", "CYP3A4", "CYP2C8"], "gold": [], "text": "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4."}, {"generated": ["DMSO", "acetonitrile", "methanol"], "gold": [], "text": "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c)."}, {"generated": ["DMSO", "acetonitrile", "methanol"], "gold": [], "text": "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c)."}, {"generated": ["DMSO", "acetonitrile", "methanol"], "gold": [], "text": "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c)."}, {"generated": ["30 min"], "gold": [], "text": "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c)."}, {"generated": ["15%\u201320%"], "gold": [], "text": "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53]."}, {"generated": ["10 mg/mL"], "gold": [], "text": "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water."}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP2C8 inhibitor", "positive CYP3A4 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP2C8 inhibitor", "positive CYP3A4 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["positive CYP2C9 inhibitor", "positive CYP2C8 inhibitor", "positive CYP3A4 inhibitor"], "gold": [], "text": "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor)."}, {"generated": ["in vitro", "drugs metabolized by CYP2C8", "CYP3A4"], "gold": [], "text": "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs."}, {"generated": ["in vitro", "drugs metabolized by CYP2C8", "CYP3A4"], "gold": [], "text": "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs."}, {"generated": ["in vitro", "drugs metabolized by CYP2C8", "CYP3A4"], "gold": [], "text": "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs."}, {"generated": ["List of ages found in text"], "gold": [], "text": "All authors reviewed the manuscript."}, {"generated": ["well tolerated", "all participants"], "gold": [], "text": "Echinacea was well tolerated, and all participants completed the study."}, {"generated": ["well tolerated", "all participants"], "gold": [], "text": "Echinacea was well tolerated, and all participants completed the study."}, {"generated": ["age"], "gold": [], "text": "2)."}, {"generated": ["eight"], "gold": [], "text": "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8]."}, {"generated": ["Subsequently"], "gold": [], "text": "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis."}, {"generated": ["docetaxel AUC0\u2013\u221e"], "gold": [], "text": "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3."}, {"generated": ["no ages found in text"], "gold": [], "text": "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used."}, {"generated": ["midazolam studies"], "gold": [], "text": "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified."}, {"generated": ["different parts of E. purpurea plants", "roots", "leaves"], "gold": [], "text": "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves."}, {"generated": ["different parts of E. purpurea plants", "roots", "leaves"], "gold": [], "text": "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves."}, {"generated": ["different parts of E. purpurea plants", "roots", "leaves"], "gold": [], "text": "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves."}, {"generated": ["alkylamides", "gene reporter assay", "CYP3A4 induction potential", "LS180 cells", "E. purpurea extracts"], "gold": [], "text": "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23]."}, {"generated": ["alkylamides", "gene reporter assay", "CYP3A4 induction potential", "LS180 cells", "E. purpurea extracts"], "gold": [], "text": "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23]."}, {"generated": ["alkylamides", "gene reporter assay", "CYP3A4 induction potential", "LS180 cells", "E. purpurea extracts"], "gold": [], "text": "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23]."}, {"generated": ["alkylamides", "gene reporter assay", "CYP3A4 induction potential", "LS180 cells", "E. purpurea extracts"], "gold": [], "text": "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23]."}, {"generated": ["alkylamides", "gene reporter assay", "CYP3A4 induction potential", "LS180 cells", "E. purpurea extracts"], "gold": [], "text": "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23]."}, {"generated": ["pharmacokinetics of docetaxel"], "gold": [], "text": "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel."}, {"generated": ["cancer patients"], "gold": [], "text": "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients."}, {"generated": ["advanced cancer"], "gold": [], "text": "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer."}, {"generated": ["product dependent"], "gold": [], "text": "Thus, the risk of CYP3A4-mediated interactions may be product dependent."}, {"generated": ["100 \u00b5L plasma", "10 \u00b5L ethyl gallate"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["100 \u00b5L plasma", "10 \u00b5L ethyl gallate"], "gold": [], "text": "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["443.10", "151.00", "139.00", "199.00", "291.20", "127.03", "307.20", "123.00"], "gold": [], "text": "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["0.1", "EC", "ECG", "EGC", "EGCG", "50 ng/mL", "500 ng/mL"], "gold": [], "text": "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC."}, {"generated": ["200 \u00b5L"], "gold": [], "text": "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA)."}, {"generated": ["Sixteen"], "gold": [], "text": "Sixteen subjects reported 27 adverse events."}, {"generated": ["adults", "mild", "children", "no specific age mentioned", "adolescents"], "gold": [], "text": "All the adverse events were mild in intensity and resolved without any treatment."}, {"generated": ["adults", "mild", "children", "no specific age mentioned", "adolescents"], "gold": [], "text": "All the adverse events were mild in intensity and resolved without any treatment."}, {"generated": ["adults", "mild", "children", "no specific age mentioned", "adolescents"], "gold": [], "text": "All the adverse events were mild in intensity and resolved without any treatment."}, {"generated": ["adults", "mild", "children", "no specific age mentioned", "adolescents"], "gold": [], "text": "All the adverse events were mild in intensity and resolved without any treatment."}, {"generated": ["adults", "mild", "children", "no specific age mentioned", "adolescents"], "gold": [], "text": "All the adverse events were mild in intensity and resolved without any treatment."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["Day 1", "Day 15"], "gold": [], "text": "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3."}, {"generated": ["Day 1", "AUC", "digoxin alone treatment"], "gold": [], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": ["Day 1", "AUC", "digoxin alone treatment"], "gold": [], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": ["Day 1", "AUC", "digoxin alone treatment"], "gold": [], "text": "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin."}, {"generated": ["reduced", "study", "systemic exposure"], "gold": [], "text": "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study."}, {"generated": ["reduced", "study", "systemic exposure"], "gold": [], "text": "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study."}, {"generated": ["reduced", "study", "systemic exposure"], "gold": [], "text": "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study."}, {"generated": ["start of the study", "mean \u00b1 SD", "ratios"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["start of the study", "mean \u00b1 SD", "ratios"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["start of the study", "mean \u00b1 SD", "ratios"], "gold": [], "text": "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables."}, {"generated": ["repeated administration group", "control group"], "gold": [], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": ["repeated administration group", "control group"], "gold": [], "text": "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group."}, {"generated": ["ginsenosides", "RGE", "1 or 2 weeks", "rats", "plasma concentrations"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["ginsenosides", "RGE", "1 or 2 weeks", "rats", "plasma concentrations"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["ginsenosides", "RGE", "1 or 2 weeks", "rats", "plasma concentrations"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["ginsenosides", "RGE", "1 or 2 weeks", "rats", "plasma concentrations"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["ginsenosides", "RGE", "1 or 2 weeks", "rats", "plasma concentrations"], "gold": [], "text": "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored."}, {"generated": ["rats"], "gold": [], "text": "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats."}, {"generated": ["rat plasma"], "gold": [], "text": "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2)."}, {"generated": ["rheumatoid arthritis"], "gold": [], "text": "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36]."}, {"generated": ["rheumatoid arthritis"], "gold": [], "text": "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis."}, {"generated": ["no ages found in text"], "gold": [], "text": "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies."}, {"generated": ["Seoul, Korea"], "gold": [], "text": "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea)."}, {"generated": ["liver samples", "100 mg"], "gold": [], "text": "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer."}, {"generated": ["liver samples", "100 mg"], "gold": [], "text": "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer."}, {"generated": ["2 h"], "gold": [], "text": "Pharmacokinetic studies started 2 h after the last RGE treatment."}, {"generated": ["Red ginseng extract"], "gold": [], "text": "Sample Availability: Red ginseng extract are available from the authors."}, {"generated": ["described entities"], "gold": [], "text": "Conceptualization, M.-K.C."}, {"generated": ["RGE"], "gold": [], "text": "Contents of ginsenosides in RGE."}, {"generated": ["2016"], "gold": [], "text": "2016; Bautista et\u00a0al."}, {"generated": ["2014"], "gold": [], "text": "2014; Dybro et\u00a0al."}, {"generated": ["3.5 \u03bcm"], "gold": [], "text": "; 3.5\u2009\u03bcm) at room temperature."}, {"generated": ["10", "-40", "3500"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["10", "-40", "3500"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["10", "-40", "3500"], "gold": [], "text": "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis."}, {"generated": ["Rat liver microsomes"], "gold": [], "text": "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC."}, {"generated": ["half-life"], "gold": [], "text": "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD."}, {"generated": ["highest recovery"], "gold": [], "text": "The highest recovery was obtained using acetonitrile as a protein precipitant."}, {"generated": ["six different rats"], "gold": [], "text": "In the present study, the selectivity was examined using independent plasma samples from six different rats."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["1", "500", "ng/mL"], "gold": [], "text": "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL."}, {"generated": ["large individual differences"], "gold": [], "text": "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed."}, {"generated": ["reports", "studies", "combinations"], "gold": [], "text": "Most of these reports and studies are on combinations with Western drugs."}, {"generated": ["reports", "studies", "combinations"], "gold": [], "text": "Most of these reports and studies are on combinations with Western drugs."}, {"generated": ["reports", "studies", "combinations"], "gold": [], "text": "Most of these reports and studies are on combinations with Western drugs."}, {"generated": ["patients with renal dysfunction", "neonates"], "gold": [], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": ["patients with renal dysfunction", "neonates"], "gold": [], "text": "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results."}, {"generated": ["our analysis of the literature"], "gold": [], "text": "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A."}, {"generated": ["experimental rats", "control rats"], "gold": [], "text": "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing)."}, {"generated": ["experimental rats", "control rats"], "gold": [], "text": "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing)."}, {"generated": ["Experiments in mice"], "gold": [], "text": "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Li Xin et al."}, {"generated": ["digoxin-induced arrhythmias", "rats"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["digoxin-induced arrhythmias", "rats"], "gold": [], "text": "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021)."}, {"generated": ["limited research"], "gold": [], "text": "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations."}, {"generated": ["complex"], "gold": [], "text": "The composition of TCM formulations is complex."}, {"generated": ["potential for herb-drug interactions"], "gold": [], "text": "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions."}, {"generated": ["systemic levels", "two or more drugs"], "gold": [], "text": "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016)."}, {"generated": ["systemic levels", "two or more drugs"], "gold": [], "text": "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016)."}, {"generated": ["none"], "gold": [], "text": "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline."}, {"generated": ["proper drug disposition"], "gold": [], "text": "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016)."}, {"generated": ["C. asiatica"], "gold": [], "text": "C. asiatica Plant Material and Preparation of CAW-R61J."}, {"generated": ["0.1% (v/v)"], "gold": [], "text": "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO."}, {"generated": ["ambient temperature"], "gold": [], "text": "Plates were thawed at ambient temperature."}, {"generated": ["means \u00b1 S.D."], "gold": [], "text": "Unless otherwise specified, all results were expressed as the means \u00b1 S.D."}, {"generated": ["age"], "gold": [], "text": "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq."}, {"generated": ["Prism 8.0.2"], "gold": [], "text": "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA)."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["mean", "standard deviation (S.D.)"], "gold": [], "text": "Mean\tS.D."}, {"generated": ["data not shown"], "gold": [], "text": "; data not shown)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["1996", "2017", "2003", "3", "2006", "2002", "2012", "2011"], "gold": [], "text": "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017)."}, {"generated": ["age"], "gold": [], "text": "An external file that holds a picture, illustration, etc."}, {"generated": ["triplicate"], "gold": [], "text": "of triplicate determinations."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["CYP3A4", "CYP2C19", "CYP2D6", "human liver microsomes", "CYP2C9", "human P450 forms"], "gold": [], "text": "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9."}, {"generated": ["clinical studies", "plasma concentrations", "CAW-R61J"], "gold": [], "text": "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract."}, {"generated": ["clinical studies", "plasma concentrations", "CAW-R61J"], "gold": [], "text": "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract."}, {"generated": ["clinical studies", "plasma concentrations", "CAW-R61J"], "gold": [], "text": "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract."}, {"generated": ["phase II"], "gold": [], "text": "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes."}, {"generated": ["chronic kidney disease"], "gold": [], "text": "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14]."}, {"generated": ["Each sample"], "gold": [], "text": "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA)."}, {"generated": ["high concentrations", "low concentrations", "medium concentrations"], "gold": [], "text": "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves."}, {"generated": ["high concentrations", "low concentrations", "medium concentrations"], "gold": [], "text": "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves."}, {"generated": ["high concentrations", "low concentrations", "medium concentrations"], "gold": [], "text": "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves."}, {"generated": ["150 \u03bcL", "berberine (IS)", "1 ng/mL"], "gold": [], "text": "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves."}, {"generated": ["150 \u03bcL", "berberine (IS)", "1 ng/mL"], "gold": [], "text": "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves."}, {"generated": ["150 \u03bcL", "berberine (IS)", "1 ng/mL"], "gold": [], "text": "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves."}, {"generated": ["24 h", "6 \u00b0C"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["24 h", "6 \u00b0C"], "gold": [], "text": "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples)."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["3 mg/kg", "10% DMSO", "5 mg/kg"], "gold": [], "text": "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO."}, {"generated": ["jejunal segments"], "gold": [], "text": "The jejunal segments were then isolated and rinsed using pre-warmed saline."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["150 \u03bcL", "50 \u03bcL", "1 ng/mL"], "gold": [], "text": "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS)."}, {"generated": ["product ion scan results", "previously published reports", "authentic standards"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["product ion scan results", "previously published reports", "authentic standards"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["product ion scan results", "previously published reports", "authentic standards"], "gold": [], "text": "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1)."}, {"generated": ["1 h after", "rat plasma samples"], "gold": [], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": ["1 h after", "rat plasma samples"], "gold": [], "text": "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide."}, {"generated": ["85", "115"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["85", "115"], "gold": [], "text": "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37]."}, {"generated": ["hypertension"], "gold": [], "text": "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy."}, {"generated": ["reported", "adults", "product ion mass spectra", "mass fragmentation patterns", "ages"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["reported", "adults", "product ion mass spectra", "mass fragmentation patterns", "ages"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["reported", "adults", "product ion mass spectra", "mass fragmentation patterns", "ages"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["reported", "adults", "product ion mass spectra", "mass fragmentation patterns", "ages"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["reported", "adults", "product ion mass spectra", "mass fragmentation patterns", "ages"], "gold": [], "text": "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1)."}, {"generated": ["experiments", "CV", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["experiments", "CV", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["experiments", "CV", "mean"], "gold": [], "text": "Data represented as mean and CV from five or six independent experiments."}, {"generated": ["chronic"], "gold": [], "text": "However, there are several challenges associated with the chronic nature of HAART administration."}, {"generated": ["developing countries"], "gold": [], "text": "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15]."}, {"generated": ["most diseases"], "gold": [], "text": "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown."}, {"generated": ["26"], "gold": [], "text": "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26]."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["bioavailable concentration", "intestinal absorption", "test compound", "soluble extract", "GI tract", "plasma concentrations"], "gold": [], "text": "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract."}, {"generated": ["mg\u00b7kg"], "gold": [], "text": "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid."}, {"generated": ["not applicable"], "gold": [], "text": "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them."}, {"generated": ["concentration-dependent inhibition"], "gold": [], "text": "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6."}, {"generated": ["24 h", "72 h"], "gold": [], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["24 h", "72 h"], "gold": [], "text": "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated."}, {"generated": ["Michelle Skelton", "Dee Blackhurst", "Kevin Dzobo", "Ambroise Wonkam", "Denis Chopera"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["Michelle Skelton", "Dee Blackhurst", "Kevin Dzobo", "Ambroise Wonkam", "Denis Chopera"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["Michelle Skelton", "Dee Blackhurst", "Kevin Dzobo", "Ambroise Wonkam", "Denis Chopera"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["Michelle Skelton", "Dee Blackhurst", "Kevin Dzobo", "Ambroise Wonkam", "Denis Chopera"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["Michelle Skelton", "Dee Blackhurst", "Kevin Dzobo", "Ambroise Wonkam", "Denis Chopera"], "gold": [], "text": "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented."}, {"generated": ["final manuscript"], "gold": [], "text": "All authors reviewed the final manuscript."}, {"generated": ["five major ingredients"], "gold": [], "text": "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs."}, {"generated": ["7 \u00b1 1-day washout period", "three treatments"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["7 \u00b1 1-day washout period", "three treatments"], "gold": [], "text": "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between."}, {"generated": ["our study"], "gold": [], "text": "Therefore, we applied this dose of GGT in our study."}, {"generated": ["1000 mg", "1000 mg \u00d7 4 times", "8 tablets"], "gold": [], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["1000 mg", "1000 mg \u00d7 4 times", "8 tablets"], "gold": [], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["1000 mg", "1000 mg \u00d7 4 times", "8 tablets"], "gold": [], "text": "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23]."}, {"generated": ["1000 mg once daily", "1000 mg \u00d7 4 times daily"], "gold": [], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["1000 mg once daily", "1000 mg \u00d7 4 times daily"], "gold": [], "text": "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week."}, {"generated": ["1000 mg", "7680 mg"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["1000 mg", "7680 mg"], "gold": [], "text": "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily."}, {"generated": ["pharmacokinetic (PK) parameters"], "gold": [], "text": "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP."}, {"generated": ["elderly subjects"], "gold": [], "text": "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects."}, {"generated": ["elderly"], "gold": [], "text": "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly."}, {"generated": ["five days"], "gold": [], "text": "Adherence to these restrictions was further emphasized five days before each probe drug administration."}, {"generated": ["ultraviolet absorption spectra", "retention times"], "gold": [], "text": "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra."}, {"generated": ["ultraviolet absorption spectra", "retention times"], "gold": [], "text": "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra."}, {"generated": ["45"], "gold": [], "text": "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation."}, {"generated": ["presupplementation", "postsupplementation"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["presupplementation", "postsupplementation"], "gold": [], "text": "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation."}, {"generated": ["17"], "gold": [], "text": "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance."}, {"generated": ["young individuals"], "gold": [], "text": "This finding also corroborates the results of an earlier study in young individuals."}, {"generated": ["54"], "gold": [], "text": "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort."}, {"generated": ["42"], "gold": [], "text": "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements."}, {"generated": ["elderly"], "gold": [], "text": "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy."}, {"generated": ["various ages found in text"], "gold": [], "text": "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides."}, {"generated": ["18"], "gold": [], "text": "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms."}, {"generated": ["specific CYP isoforms", "little effect"], "gold": [], "text": "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study."}, {"generated": ["specific CYP isoforms", "little effect"], "gold": [], "text": "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study."}, {"generated": ["conventional medications"], "gold": [], "text": "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions."}, {"generated": ["plasma quinine", "3-hydroxyquinine", "HPLC method"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "3-hydroxyquinine", "HPLC method"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["plasma quinine", "3-hydroxyquinine", "HPLC method"], "gold": [], "text": "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["10", "6", "11", "8", "9", "7"], "gold": [], "text": "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola."}, {"generated": ["adverse side effects from taking G. kola seeds", "histories of hypersensitivity to quinine or similar agents", "breastfeeding", "pregnancy"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds", "histories of hypersensitivity to quinine or similar agents", "breastfeeding", "pregnancy"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds", "histories of hypersensitivity to quinine or similar agents", "breastfeeding", "pregnancy"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["adverse side effects from taking G. kola seeds", "histories of hypersensitivity to quinine or similar agents", "breastfeeding", "pregnancy"], "gold": [], "text": "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study."}, {"generated": ["certified healthy", "written informed consent"], "gold": [], "text": "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol."}, {"generated": ["certified healthy", "written informed consent"], "gold": [], "text": "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol."}, {"generated": ["600 mg quinine sulphate tablets", "overnight fast"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["600 mg quinine sulphate tablets", "overnight fast"], "gold": [], "text": "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England)."}, {"generated": ["1, 2, 3, 4, 6, 8, 12, 24, 36, 48 h"], "gold": [], "text": "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola."}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": [], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": ["0.37\u00b5g/ml", "0.5\u00b5g/ml"], "gold": [], "text": "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively."}, {"generated": ["0\u2013\u221e"], "gold": [], "text": "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %."}, {"generated": ["very light dizziness"], "gold": [], "text": "Precisely, only 3 participants complained of very light dizziness."}, {"generated": ["38"], "gold": [], "text": "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination."}, {"generated": ["CL/F", "T1/2"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["CL/F", "T1/2"], "gold": [], "text": "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola."}, {"generated": ["not applicable"], "gold": [], "text": "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials."}, {"generated": ["77"], "gold": [], "text": "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo."}, {"generated": ["adults", "KwaZulu-Natal", "worldwide"], "gold": [], "text": "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11]."}, {"generated": ["adults", "KwaZulu-Natal", "worldwide"], "gold": [], "text": "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11]."}, {"generated": ["adults", "KwaZulu-Natal", "worldwide"], "gold": [], "text": "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11]."}, {"generated": ["1200 mg"], "gold": [], "text": "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group."}, {"generated": ["serial electrocardiograms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "both arms"], "gold": [], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["serial electrocardiograms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "both arms"], "gold": [], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["serial electrocardiograms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "both arms"], "gold": [], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["serial electrocardiograms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "both arms"], "gold": [], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["serial electrocardiograms", "corrected QT interval (QTc)", "PR interval", "QRS duration", "both arms"], "gold": [], "text": "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table)."}, {"generated": ["ages found in text"], "gold": [], "text": "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time."}, {"generated": ["percent", "prevalence", "occurrence", "data"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["percent", "prevalence", "occurrence", "data"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["percent", "prevalence", "occurrence", "data"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["percent", "prevalence", "occurrence", "data"], "gold": [], "text": "Data were reported as prevalence (percent) of the occurrence."}, {"generated": ["chronic kidney disease (CKD)", "increasing incidence"], "gold": [], "text": "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment."}, {"generated": ["chronic kidney disease (CKD)", "increasing incidence"], "gold": [], "text": "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment."}, {"generated": ["not specified"], "gold": [], "text": "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously."}, {"generated": ["patients' age"], "gold": [], "text": "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study."}, {"generated": ["13.23%"], "gold": [], "text": "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury."}, {"generated": ["middle-aged (50\u201364)"], "gold": ["50\u201364"], "text": "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups."}, {"generated": ["27"], "gold": [], "text": "[27] In the study performed by Roozbeh et al."}, {"generated": ["90%"], "gold": [], "text": "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM)."}, {"generated": ["18 F", "2 months"], "gold": [], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["18 F", "2 months"], "gold": [], "text": "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy."}, {"generated": ["0.5 mL", "6 min"], "gold": [], "text": "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min."}, {"generated": ["0.5 mL", "6 min"], "gold": [], "text": "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min."}, {"generated": ["each blood sampling time"], "gold": [], "text": "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser."}, {"generated": ["standard human plasma", "known factor activity", "clotting time"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["standard human plasma", "known factor activity", "clotting time"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["standard human plasma", "known factor activity", "clotting time"], "gold": [], "text": "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["dose", "ln 2/kel", "CL/kel", "apparent volume of distribution (V/F)", "half-life", "AUC0-\u221e", "apparent clearance (CL/F)"], "gold": [], "text": "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "INR data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "INR data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "INR data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["two-compartment pharmacokinetic model", "percentage of prothrombin complex activity (PCA)", "S-warfarin concentration-time data", "INR data"], "gold": [], "text": "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration."}, {"generated": ["data not shown"], "gold": [], "text": "However, this did not reach statistical significance (data not shown)."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["0.010 (0.007\u20130.013)", "1.3 (1.1\u20131.6)", "NA", "1.12 (0.39\u20131.84)", "1.06 (0.83\u20131.19)", "60.3 (54.5\u201366.1)", "0.010 (0.007\u20130.014)", "1.9 (1.1\u20132.7)", "1.06 (0.95\u20131.19)", "1.7 (1.5\u20132.0)", "1.8 (1.7\u20131.9)", "63.0 (57.3\u201368.8)", "65.5 (55.3\u201375.6)", "1.04 (0.94\u20131.67)", "1.9 (1.5\u20132.2)", "1.4 (1.1\u20131.6)", "0.94 (0.67\u20131.47)"], "gold": [], "text": "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax."}, {"generated": ["2007"], "gold": [], "text": "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin."}, {"generated": ["7 patients"], "gold": [], "text": "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al."}, {"generated": ["2007"], "gold": [], "text": "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess."}, {"generated": ["common", "adults", "patients"], "gold": [], "text": "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking."}, {"generated": ["common", "adults", "patients"], "gold": [], "text": "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking."}, {"generated": ["common", "adults", "patients"], "gold": [], "text": "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking."}, {"generated": ["popular publications", "directed to cancer patients", "information websites", "recent"], "gold": [], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["popular publications", "directed to cancer patients", "information websites", "recent"], "gold": [], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["popular publications", "directed to cancer patients", "information websites", "recent"], "gold": [], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["popular publications", "directed to cancer patients", "information websites", "recent"], "gold": [], "text": "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs."}, {"generated": ["elderly"], "gold": [], "text": "It therefore was recommended that they should be avoided in the elderly [10, 12]."}, {"generated": ["600 mg"], "gold": [], "text": "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets."}, {"generated": ["conclusions", "results", "studies", "data"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["conclusions", "results", "studies", "data"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["conclusions", "results", "studies", "data"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["conclusions", "results", "studies", "data"], "gold": [], "text": "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions."}, {"generated": ["described entities"], "gold": [], "text": "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results."}, {"generated": ["36"], "gold": [], "text": "[36]."}, {"generated": ["14 subsequent days"], "gold": [], "text": "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days."}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "1-hydroxymidazolam/midazolam serum ratio", "paraxanthine/caffeine serum ratio"], "gold": [], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "1-hydroxymidazolam/midazolam serum ratio", "paraxanthine/caffeine serum ratio"], "gold": [], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "1-hydroxymidazolam/midazolam serum ratio", "paraxanthine/caffeine serum ratio"], "gold": [], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": ["hydroxychlorzoxazone/chlorzoxazone serum ratio", "debrisoquine urinary recovery ratio", "1-hydroxymidazolam/midazolam serum ratio", "paraxanthine/caffeine serum ratio"], "gold": [], "text": "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined."}, {"generated": ["12 weeks", "15 days"], "gold": [], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["12 weeks", "15 days"], "gold": [], "text": "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51]."}, {"generated": ["not applicable"], "gold": [], "text": "The results were not presented in detail but indicated that the two drugs act independently from each other."}, {"generated": ["two case reports"], "gold": [], "text": "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports."}, {"generated": ["clinical risks", "essential"], "gold": [], "text": "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks."}, {"generated": ["clinical risks", "essential"], "gold": [], "text": "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks."}, {"generated": ["in vitro", "in vivo"], "gold": [], "text": "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data."}, {"generated": ["in vitro", "in vivo"], "gold": [], "text": "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data."}, {"generated": ["valid clinical observations", "relevant risk"], "gold": [], "text": "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations."}, {"generated": ["valid clinical observations", "relevant risk"], "gold": [], "text": "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations."}, {"generated": ["P-gp", "UGT", "CYP-isoenzymes"], "gold": [], "text": "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data."}, {"generated": ["P-gp", "UGT", "CYP-isoenzymes"], "gold": [], "text": "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data."}, {"generated": ["P-gp", "UGT", "CYP-isoenzymes"], "gold": [], "text": "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data."}, {"generated": ["no ages found in text"], "gold": [], "text": "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence."}, {"generated": ["7 days"], "gold": [], "text": "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively."}, {"generated": ["normalization of the LVEF", "rapid improvement", "regression of the radiological abnormalities"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["normalization of the LVEF", "rapid improvement", "regression of the radiological abnormalities"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["normalization of the LVEF", "rapid improvement", "regression of the radiological abnormalities"], "gold": [], "text": "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF."}, {"generated": ["drug-induced cardiopulmonary toxicity"], "gold": [], "text": "This was an important case of drug-induced cardiopulmonary toxicity."}, {"generated": ["probably associated with venlafaxine"], "gold": [], "text": "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine."}, {"generated": ["metaboliza\u00e7\u00e3o lenta", "circunstancial"], "gold": [], "text": "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente."}, {"generated": ["metaboliza\u00e7\u00e3o lenta", "circunstancial"], "gold": [], "text": "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente."}, {"generated": ["maioria"], "gold": [], "text": "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada."}, {"generated": ["35 anos de idade"], "gold": [], "text": "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas."}, {"generated": ["menopausal symptoms"], "gold": [], "text": "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms."}, {"generated": ["date of onset", "result of adverse reaction", "degree of adverse reaction", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["date of onset", "result of adverse reaction", "degree of adverse reaction", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["date of onset", "result of adverse reaction", "degree of adverse reaction", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["date of onset", "result of adverse reaction", "degree of adverse reaction", "date of disappearance"], "gold": [], "text": "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included."}, {"generated": ["statistically significant difference", "ages", "demographic information"], "gold": [], "text": "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups."}, {"generated": ["statistically significant difference", "ages", "demographic information"], "gold": [], "text": "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups."}, {"generated": ["statistically significant difference", "ages", "demographic information"], "gold": [], "text": "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups."}, {"generated": ["p-value", "Fisher's exact test"], "gold": [], "text": "p-value by Fisher's exact test."}, {"generated": ["p-value", "Fisher's exact test"], "gold": [], "text": "p-value by Fisher's exact test."}, {"generated": ["fully recovered"], "gold": [], "text": "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group."}, {"generated": ["no ages found in text"], "gold": [], "text": "It is noteworthy that no severe adverse reactions were observed in this study."}, {"generated": ["large-scale", "long period"], "gold": [], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["large-scale", "long period"], "gold": [], "text": "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects."}, {"generated": ["UGT1A1", "UGT2B7"], "gold": [], "text": "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation."}, {"generated": ["UGT1A1", "UGT2B7"], "gold": [], "text": "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation."}, {"generated": ["intersection", "second quadrant", "Lineweaver-Burk plots", "vertical axis", "Dixon"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["intersection", "second quadrant", "Lineweaver-Burk plots", "vertical axis", "Dixon"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["intersection", "second quadrant", "Lineweaver-Burk plots", "vertical axis", "Dixon"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["intersection", "second quadrant", "Lineweaver-Burk plots", "vertical axis", "Dixon"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["intersection", "second quadrant", "Lineweaver-Burk plots", "vertical axis", "Dixon"], "gold": [], "text": "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive."}, {"generated": ["0.49 \u03bcM"], "gold": [], "text": "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM."}, {"generated": ["13-fold", "120-fold"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["13-fold", "120-fold"], "gold": [], "text": "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24]."}, {"generated": ["many drugs"], "gold": [], "text": "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25]."}, {"generated": ["previous"], "gold": [], "text": "The previous study performed by Du et al."}, {"generated": ["AGE: Not specified"], "gold": [], "text": "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation."}, {"generated": ["chronic liver disease"], "gold": [], "text": "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8]."}, {"generated": ["0.5\u20132.0 g/kg"], "gold": [], "text": "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12]."}, {"generated": ["rats", "human"], "gold": [], "text": "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides."}, {"generated": ["rats", "human"], "gold": [], "text": "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides."}, {"generated": ["valsartan", "RGE", "high dose", "repeated administration", "Rc"], "gold": [], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": ["valsartan", "RGE", "high dose", "repeated administration", "Rc"], "gold": [], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": ["valsartan", "RGE", "high dose", "repeated administration", "Rc"], "gold": [], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": ["valsartan", "RGE", "high dose", "repeated administration", "Rc"], "gold": [], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": ["valsartan", "RGE", "high dose", "repeated administration", "Rc"], "gold": [], "text": "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["34.1 \u03bcM", "7.8 \u03bcM", "0.1\u20130.2%", "0.4\u20130.5%"], "gold": [], "text": "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B)."}, {"generated": ["16,000\u00d7 g", "50 \u03bcL", "\u221280 \u00b0C", "10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["16,000\u00d7 g", "50 \u03bcL", "\u221280 \u00b0C", "10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["16,000\u00d7 g", "50 \u03bcL", "\u221280 \u00b0C", "10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["16,000\u00d7 g", "50 \u03bcL", "\u221280 \u00b0C", "10 min"], "gold": [], "text": "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1.5", "0.67", "0.33", "8", "4", "24", "48", "0.17", "2"], "gold": [], "text": "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing."}, {"generated": ["1-week"], "gold": [], "text": "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE)."}, {"generated": ["0 to 48 h"], "gold": [], "text": "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats."}, {"generated": ["\u00b11 day"], "gold": [], "text": "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted."}, {"generated": ["24 subjects"], "gold": [], "text": "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised."}, {"generated": ["malondialdehyde (MDA)"], "gold": [], "text": "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3]."}, {"generated": ["disease of antioxidant deficiency"], "gold": [], "text": "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13]."}, {"generated": ["markedly"], "gold": [], "text": "Furthermore, it decreases insulin and blood glucose markedly [17]."}, {"generated": ["OS"], "gold": [], "text": "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18]."}, {"generated": ["C. sinensis"], "gold": [], "text": "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19]."}, {"generated": ["1 mL", "120 g", "4 \u00b0C", "200 \u00b5L", "4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["1 mL", "120 g", "4 \u00b0C", "200 \u00b5L", "4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["1 mL", "120 g", "4 \u00b0C", "200 \u00b5L", "4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["1 mL", "120 g", "4 \u00b0C", "200 \u00b5L", "4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["1 mL", "120 g", "4 \u00b0C", "200 \u00b5L", "4 h"], "gold": [], "text": "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses."}, {"generated": ["0.54\u20131,32 pg/mL", "1,1\u2032,3,3\u2032-tetramethoxypropane"], "gold": [], "text": "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL)."}, {"generated": ["0.54\u20131,32 pg/mL", "1,1\u2032,3,3\u2032-tetramethoxypropane"], "gold": [], "text": "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL)."}, {"generated": ["described"], "gold": [], "text": "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable."}, {"generated": ["75", "25"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["75", "25"], "gold": [], "text": "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25)."}, {"generated": ["group 2", "group 1", "group 3"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["group 2", "group 1", "group 3"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["group 2", "group 1", "group 3"], "gold": [], "text": "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1."}, {"generated": ["FBS level", "pancreatic \u03b2 cells"], "gold": [], "text": "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56]."}, {"generated": ["FBS level", "pancreatic \u03b2 cells"], "gold": [], "text": "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56]."}, {"generated": ["significant reduction", "glucose levels", "insulin tolerance"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["significant reduction", "glucose levels", "insulin tolerance"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["significant reduction", "glucose levels", "insulin tolerance"], "gold": [], "text": "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61]."}, {"generated": ["described entities"], "gold": [], "text": "All of this research is consistent with our study."}, {"generated": ["proliferative and secretory phases", "longer follow-up"], "gold": [], "text": "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up."}, {"generated": ["proliferative and secretory phases", "longer follow-up"], "gold": [], "text": "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up."}, {"generated": ["patients"], "gold": [], "text": "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram."}, {"generated": ["20", "2006"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["20", "2006"], "gold": [], "text": "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006)."}, {"generated": ["V05895B"], "gold": [], "text": "V05895B; Arkopharma, Madrid, Spain)."}, {"generated": ["days 0, 14, and 28"], "gold": [], "text": "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28."}, {"generated": ["treatment", "natural log transformed", "confidence intervals", "analysis of variance model"], "gold": [], "text": "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect."}, {"generated": ["treatment", "natural log transformed", "confidence intervals", "analysis of variance model"], "gold": [], "text": "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect."}, {"generated": ["treatment", "natural log transformed", "confidence intervals", "analysis of variance model"], "gold": [], "text": "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect."}, {"generated": ["treatment", "natural log transformed", "confidence intervals", "analysis of variance model"], "gold": [], "text": "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect."}, {"generated": ["<50 copies/ml"], "gold": [], "text": "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study."}, {"generated": ["Darunavir"], "gold": [], "text": "Darunavir pharmacokinetics."}, {"generated": ["antiretroviral agents", "clinical pharmacokinetic interactions", "botanicals"], "gold": [], "text": "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature."}, {"generated": ["antiretroviral agents", "clinical pharmacokinetic interactions", "botanicals"], "gold": [], "text": "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature."}, {"generated": ["antiretroviral agents", "clinical pharmacokinetic interactions", "botanicals"], "gold": [], "text": "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature."}, {"generated": ["darunavir pharmacokinetics", "variability"], "gold": [], "text": "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy."}, {"generated": ["darunavir pharmacokinetics", "variability"], "gold": [], "text": "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy."}, {"generated": ["no relevant effect on the in vivo activity of the major CYP enzymes in humans"], "gold": [], "text": "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions."}, {"generated": ["variety of disorders"], "gold": [], "text": "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders."}, {"generated": ["8 days"], "gold": [], "text": "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C)."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["MID assays", "precipitation", "DEX", "internal standard", "DOR", "OME", "5-OH-OME"], "gold": [], "text": "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively."}, {"generated": ["standard bioequivalence approach"], "gold": [], "text": "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins."}, {"generated": ["120"], "gold": [], "text": "Administration of EGb 761\u00ae 120\u00a0mg b.i.d."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "1 week"], "gold": [], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["240-mg EGb 761\u00ae daily dose", "1 week"], "gold": [], "text": "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35]."}, {"generated": ["8-day period"], "gold": [], "text": "does not affect CYP2C19 activity when administered over an 8-day period."}, {"generated": ["pharmacodynamic (PD)", "randomized controlled trials", "pharmacokinetic (PK)"], "gold": [], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": ["pharmacodynamic (PD)", "randomized controlled trials", "pharmacokinetic (PK)"], "gold": [], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": ["pharmacodynamic (PD)", "randomized controlled trials", "pharmacokinetic (PK)"], "gold": [], "text": "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin."}, {"generated": ["age found in text"], "gold": [], "text": "Type of participant."}, {"generated": ["standard eligibility inclusion criteria"], "gold": [], "text": "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers."}, {"generated": ["28", "29", "21", "24", "26"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["28", "29", "21", "24", "26"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["28", "29", "21", "24", "26"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["28", "29", "21", "24", "26"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["28", "29", "21", "24", "26"], "gold": [], "text": "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal."}, {"generated": ["high risk of bias", "unclear risk of bias", "minimum age", "minus (-) marked circle"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["high risk of bias", "unclear risk of bias", "minimum age", "minus (-) marked circle"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["high risk of bias", "unclear risk of bias", "minimum age", "minus (-) marked circle"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["high risk of bias", "unclear risk of bias", "minimum age", "minus (-) marked circle"], "gold": [], "text": "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias."}, {"generated": ["different ages found in text"], "gold": [], "text": "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study."}, {"generated": ["potential herb-warfarin interaction"], "gold": [], "text": "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship."}, {"generated": ["multiple reasons"], "gold": [], "text": "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40]."}, {"generated": ["drugs metabolized by CYP2C9", "in vivo study"], "gold": [], "text": "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47]."}, {"generated": ["drugs metabolized by CYP2C9", "in vivo study"], "gold": [], "text": "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47]."}, {"generated": ["dose-dependent manner", "in vivo study", "hepatic damage", "48"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["dose-dependent manner", "in vivo study", "hepatic damage", "48"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["dose-dependent manner", "in vivo study", "hepatic damage", "48"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["dose-dependent manner", "in vivo study", "hepatic damage", "48"], "gold": [], "text": "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48]."}, {"generated": ["no ages found in text"], "gold": [], "text": "However, no studies were reported these data."}, {"generated": ["no history of warfarin use", "detected in her blood serum analysis"], "gold": [], "text": "She had no history of warfarin use, but warfarin was detected in her blood serum analysis."}, {"generated": ["no history of warfarin use", "detected in her blood serum analysis"], "gold": [], "text": "She had no history of warfarin use, but warfarin was detected in her blood serum analysis."}, {"generated": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["more than 37 seconds", "greater than seven", "more than 70 seconds"], "gold": [], "text": "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven."}, {"generated": ["unknown DIC", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption", "unknown pathologic inhibitors"], "gold": [], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["unknown DIC", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption", "unknown pathologic inhibitors"], "gold": [], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["unknown DIC", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption", "unknown pathologic inhibitors"], "gold": [], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["unknown DIC", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption", "unknown pathologic inhibitors"], "gold": [], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["unknown DIC", "unknown coagulopathy", "unknown origin", "unknown vitamin K malabsorption", "unknown pathologic inhibitors"], "gold": [], "text": "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6)."}, {"generated": ["subject enrollment", "study protocol"], "gold": [], "text": "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment."}, {"generated": ["subject enrollment", "study protocol"], "gold": [], "text": "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable."}, {"generated": ["age"], "gold": [], "text": "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms."}, {"generated": ["well\u2010characterized composition", "in vitro inhibitory potency", "human pharmacokinetic data"], "gold": [], "text": "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction."}, {"generated": ["well\u2010characterized composition", "in vitro inhibitory potency", "human pharmacokinetic data"], "gold": [], "text": "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction."}, {"generated": ["well\u2010characterized composition", "in vitro inhibitory potency", "human pharmacokinetic data"], "gold": [], "text": "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction."}, {"generated": ["multiple dosing", "silibinin predosing", "alternate study designs", "raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["multiple dosing", "silibinin predosing", "alternate study designs", "raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["multiple dosing", "silibinin predosing", "alternate study designs", "raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["multiple dosing", "silibinin predosing", "alternate study designs", "raloxifene"], "gold": [], "text": "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential."}, {"generated": ["oxidative metabolism", "conjugative metabolism"], "gold": [], "text": "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development."}, {"generated": ["oxidative metabolism", "conjugative metabolism"], "gold": [], "text": "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development."}, {"generated": ["95%"], "gold": [], "text": "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA)."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["8-hour", "6-hour", "12-hour", "10-hour", "3-hour", "4-hour"], "gold": [], "text": "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control."}, {"generated": ["curcumin"], "gold": [], "text": "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier."}, {"generated": ["existing literature", "comprehensive systematic review"], "gold": [], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": ["existing literature", "comprehensive systematic review"], "gold": [], "text": "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions."}, {"generated": ["2012"], "gold": [], "text": "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec."}, {"generated": ["2012"], "gold": [], "text": "2012)."}, {"generated": ["rabbits", "human"], "gold": [], "text": "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365]."}, {"generated": ["rabbits", "human"], "gold": [], "text": "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365]."}, {"generated": ["rats", "two children"], "gold": [], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": ["rats", "two children"], "gold": [], "text": "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70]."}, {"generated": ["long-term basis"], "gold": [], "text": "Patients on antiepileptic therapy are usually on a long-term basis."}, {"generated": ["reduced the plasma level of CBZ"], "gold": [], "text": "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption."}, {"generated": ["Caution"], "gold": [], "text": "Caution should also be paid for beverage containing alcohol."}, {"generated": ["patients with major depression or bipolar disorder"], "gold": [], "text": "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder."}, {"generated": ["proactive monitoring"], "gold": [], "text": "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines."}, {"generated": ["variables", "p < 0.05", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["variables", "p < 0.05", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["variables", "p < 0.05", "significant relationship"], "gold": [], "text": "A significant relationship between variables was identified if p < 0.05."}, {"generated": ["List of ages found in text"], "gold": [], "text": "A summary of the background characteristics of the interviewed patients is given in Table 1."}, {"generated": ["that age group", "highest number of patients with type-2 diabetes"], "gold": [], "text": "This is possibly because the highest number of patients with type-2 diabetes fell within that age group."}, {"generated": ["that age group", "highest number of patients with type-2 diabetes"], "gold": [], "text": "This is possibly because the highest number of patients with type-2 diabetes fell within that age group."}, {"generated": ["pharmacological management", "hypoglycaemic agents", "Tabular summary", "patients"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["pharmacological management", "hypoglycaemic agents", "Tabular summary", "patients"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["pharmacological management", "hypoglycaemic agents", "Tabular summary", "patients"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["pharmacological management", "hypoglycaemic agents", "Tabular summary", "patients"], "gold": [], "text": "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents."}, {"generated": ["12 identified plants"], "gold": [], "text": "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published."}, {"generated": ["patients with diabetes"], "gold": [], "text": "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions."}, {"generated": ["thousands of years"], "gold": [], "text": "Herbs have been used for primary health care for thousands of years before the advent of modern medicines."}, {"generated": ["hepatocellular carcinoma"], "gold": [], "text": "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7]."}, {"generated": ["15 min"], "gold": [], "text": "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12]."}, {"generated": ["22 compounds"], "gold": [], "text": "A total of 22 compounds were identified or tentatively identified (Figure 1)."}, {"generated": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "gold": [], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "gold": [], "text": "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL)."}, {"generated": ["human"], "gold": [], "text": "Liver drug enzymes are the common sites of drug interaction in human."}, {"generated": ["LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "notoginsenoside R", "Ultimate 3000 UPLC system"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "notoginsenoside R", "Ultimate 3000 UPLC system"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "notoginsenoside R", "Ultimate 3000 UPLC system"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["LTQ-Orbitrap Elite mass spectrometer", "UPLC-MS/MS analysis", "notoginsenoside R", "Ultimate 3000 UPLC system"], "gold": [], "text": "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)."}, {"generated": ["2 \u00d7 10 Total RNA"], "gold": [], "text": "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China)."}, {"generated": ["whole experiments"], "gold": [], "text": "conceived and designed the whole experiments."}, {"generated": ["p < 0.001", "p < 0.01"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["p < 0.001", "p < 0.01"], "gold": [], "text": "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively)."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["cytochrome P450 enzymes", "drug transporters", "CYPs"], "gold": [], "text": "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates."}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": [], "text": "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown)."}, {"generated": ["L-MDR1 cells", "human P-glycoprotein (P-gp)"], "gold": [], "text": "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown)."}, {"generated": ["minor effect"], "gold": [], "text": "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B)."}, {"generated": ["in vitro"], "gold": [], "text": "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters."}, {"generated": ["concomitantly used drugs"], "gold": [], "text": "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17]."}, {"generated": ["MDCKII-BCRP cells", "parental cell line MDCKII"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["MDCKII-BCRP cells", "parental cell line MDCKII"], "gold": [], "text": "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24]."}, {"generated": ["published previously", "positively controls"], "gold": [], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": ["published previously", "positively controls"], "gold": [], "text": "Results for the positive controls rifampicin and cyclosporine A were published previously [25]."}, {"generated": ["1%", "Banderol", "Samento"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["1%", "Banderol", "Samento"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["1%", "Banderol", "Samento"], "gold": [], "text": "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay."}, {"generated": ["miniprep Kit", "RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit"], "gold": [], "text": "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions."}, {"generated": ["miniprep Kit", "RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit"], "gold": [], "text": "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions."}, {"generated": ["previous"], "gold": [], "text": "Data were evaluated as described previously [28]."}, {"generated": ["no ages found in text"], "gold": [], "text": "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript."}, {"generated": ["Reporter gene assays"], "gold": [], "text": "Results of the reporter gene assays."}, {"generated": ["four days"], "gold": [], "text": "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure."}, {"generated": ["LS180 cells"], "gold": [], "text": "Effect of Samento on CYP2J2 mRNA decay in LS180 cells."}, {"generated": ["t = 0"], "gold": [], "text": "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0."}, {"generated": ["original formulation"], "gold": [], "text": "Its original formulation was in a tablet form."}, {"generated": ["2 weeks"], "gold": [], "text": "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period."}, {"generated": ["throughout the study"], "gold": [], "text": "Safety monitoring was performed throughout the study."}, {"generated": ["5500 V", "500\u00b0C"], "gold": [], "text": "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C."}, {"generated": ["5500 V", "500\u00b0C"], "gold": [], "text": "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C."}, {"generated": ["0,\u221e"], "gold": [], "text": "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion."}, {"generated": ["90% confidence intervals"], "gold": [], "text": "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data."}, {"generated": ["no ages found in text"], "gold": [], "text": "No clinically significant alterations in blood pressure, heart rate or body temperature were observed."}, {"generated": ["different types of statins"], "gold": [], "text": "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types."}, {"generated": ["69.90%", "65.38%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05)."}, {"generated": ["69.90%", "65.38%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05)."}, {"generated": ["Figure 5A,B"], "gold": [], "text": "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B."}, {"generated": ["66.77%", "41.06%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["66.77%", "41.06%"], "gold": [], "text": "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05)."}, {"generated": ["pharmacokinetic disposition"], "gold": [], "text": "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25]."}, {"generated": ["DAS", "determine", "pharmacokinetic interaction"], "gold": [], "text": "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact."}, {"generated": ["DAS", "determine", "pharmacokinetic interaction"], "gold": [], "text": "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact."}, {"generated": ["DAS", "determine", "pharmacokinetic interaction"], "gold": [], "text": "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact."}, {"generated": ["DAS 25 mg/kg"], "gold": [], "text": "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O."}, {"generated": ["12-h", "12 h", "one week"], "gold": [], "text": "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment."}, {"generated": ["12-h", "12 h", "one week"], "gold": [], "text": "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment."}, {"generated": ["12-h", "12 h", "one week"], "gold": [], "text": "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment."}, {"generated": ["25 mg/kg", "7 days", "Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["25 mg/kg", "7 days", "Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["25 mg/kg", "7 days", "Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["25 mg/kg", "7 days", "Group I", "Group II"], "gold": [], "text": "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day."}, {"generated": ["2 hours", "7th day", "7 days", "40 mg/kg"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 hours", "7th day", "7 days", "40 mg/kg"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 hours", "7th day", "7 days", "40 mg/kg"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["2 hours", "7th day", "7 days", "40 mg/kg"], "gold": [], "text": "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days."}, {"generated": ["positive direction", "electrospray ionization"], "gold": [], "text": "Electrospray ionization was used to ionize samples in a positive direction."}, {"generated": ["positive direction", "electrospray ionization"], "gold": [], "text": "Electrospray ionization was used to ionize samples in a positive direction."}, {"generated": ["in vivo studies", "humans"], "gold": [], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": ["in vivo studies", "humans"], "gold": [], "text": "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings."}, {"generated": ["List of ages found in text"], "gold": [], "text": "; supervision, K.M.A."}, {"generated": ["described entities"], "gold": [], "text": "All authors have read and agreed to the published version of the manuscript."}, {"generated": ["KSU-SE-21-58"], "gold": [], "text": "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58)."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["average age", "age group", "standard deviation", "sample age", "age range", "patient age", "subject age", "mean age"], "gold": [], "text": "All results are presented as the average \u00b1 SD."}, {"generated": ["APG pretreatment", "rats", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["APG pretreatment", "rats", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["APG pretreatment", "rats", "DAS administration"], "gold": [], "text": "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment."}, {"generated": ["herb-mediated changes", "population"], "gold": [], "text": "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population."}, {"generated": ["herb-mediated changes", "population"], "gold": [], "text": "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population."}, {"generated": ["elderly"], "gold": [], "text": "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly."}, {"generated": ["adult women"], "gold": [], "text": "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women."}, {"generated": ["26", "27"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["26", "27"], "gold": [], "text": "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27]."}, {"generated": ["\u221280 \u00b0C"], "gold": [], "text": "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C."}, {"generated": ["height, weight, or BMI at baseline"], "gold": [], "text": "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1)."}, {"generated": ["baseline", "12 weeks"], "gold": [], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["baseline", "12 weeks"], "gold": [], "text": "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2."}, {"generated": ["about 20 years ago"], "gold": [], "text": "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago."}, {"generated": ["pregnane-X-receptor"], "gold": [], "text": "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["2019", "2017", "2004", "2009", "2006", "2012"], "gold": [], "text": "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006)."}, {"generated": ["potentially relevant targets for depression"], "gold": [], "text": "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression."}, {"generated": ["time of immobility"], "gold": [], "text": "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test."}, {"generated": ["2018", "2019", "recently"], "gold": [], "text": "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019)."}, {"generated": ["2018", "2019", "recently"], "gold": [], "text": "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019)."}, {"generated": ["2018", "2019", "recently"], "gold": [], "text": "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019)."}, {"generated": ["seven test drugs", "low\u2010hyperforin"], "gold": [], "text": "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019)."}, {"generated": ["seven test drugs", "low\u2010hyperforin"], "gold": [], "text": "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019)."}, {"generated": ["cancer therapies", "high quality clinical data"], "gold": [], "text": "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies."}, {"generated": ["cancer therapies", "high quality clinical data"], "gold": [], "text": "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies."}, {"generated": ["Lingzhi", "Yunzhi"], "gold": [], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["Lingzhi", "Yunzhi"], "gold": [], "text": "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions."}, {"generated": ["significant dosage differences"], "gold": [], "text": "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group."}, {"generated": ["Figure 1"], "gold": [], "text": "Figure\u00a01 summarizes the process of database searching and literature selection."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["20", "141", "98", "101", "83", "144", "84", "111", "67", "103", "105", "63", "145", "99"], "gold": [], "text": "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["tumor cell angiogenesis", "reactive oxygen species production"], "gold": [], "text": "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124]."}, {"generated": ["gut dysbiosis induced by paclitaxel", "recent study", "tumor metabolism"], "gold": [], "text": "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97]."}, {"generated": ["gut dysbiosis induced by paclitaxel", "recent study", "tumor metabolism"], "gold": [], "text": "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97]."}, {"generated": ["gut dysbiosis induced by paclitaxel", "recent study", "tumor metabolism"], "gold": [], "text": "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97]."}, {"generated": ["age"], "gold": [], "text": "a."}, {"generated": ["Multiple ages not specified"], "gold": [], "text": "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171]."}, {"generated": ["adverse effects", "chemotherapeutic drugs", "clinical settings"], "gold": [], "text": "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings."}, {"generated": ["adverse effects", "chemotherapeutic drugs", "clinical settings"], "gold": [], "text": "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings."}, {"generated": ["adverse effects", "chemotherapeutic drugs", "clinical settings"], "gold": [], "text": "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings."}, {"generated": ["Table S4"], "gold": [], "text": "Table S4."}, {"generated": ["described ages found in text"], "gold": [], "text": "Not applicable."}, {"generated": ["conventional cancer therapy", "frequently"], "gold": [], "text": "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy."}, {"generated": ["conventional cancer therapy", "frequently"], "gold": [], "text": "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy."}, {"generated": ["70\u201380%"], "gold": [], "text": "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer."}, {"generated": ["breast cancer patients", "other types of cancer"], "gold": [], "text": "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313]."}, {"generated": ["breast cancer patients", "other types of cancer"], "gold": [], "text": "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313]."}, {"generated": ["5\u2009mg", "306\u2009ng/mL"], "gold": [], "text": "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec."}, {"generated": ["5\u2009mg", "306\u2009ng/mL"], "gold": [], "text": "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d", "human liver microsomes", "\u03b2-estradiol"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d", "human liver microsomes", "\u03b2-estradiol"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d", "human liver microsomes", "\u03b2-estradiol"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d", "human liver microsomes", "\u03b2-estradiol"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["4-hydroxy-N-desmethyltamoxifen hydrochloride", "HLMs", "dextrorphan-d", "human liver microsomes", "\u03b2-estradiol"], "gold": [], "text": "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA)."}, {"generated": ["concentration-dependent inhibition of proliferation"], "gold": [], "text": "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig."}, {"generated": ["metabolizers", "enzyme phenotypes", "patients"], "gold": [], "text": "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33]."}, {"generated": ["metabolizers", "enzyme phenotypes", "patients"], "gold": [], "text": "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33]."}, {"generated": ["metabolizers", "enzyme phenotypes", "patients"], "gold": [], "text": "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33]."}, {"generated": ["studies", "long-term outcomes"], "gold": [], "text": "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35]."}, {"generated": ["studies", "long-term outcomes"], "gold": [], "text": "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35]."}, {"generated": ["50 donors"], "gold": [], "text": "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41]."}, {"generated": ["described entities"], "gold": [], "text": "(PDF 36 kb) Figure S2."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["0.1", "1", "5", "10", "100", "2"], "gold": [], "text": "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM)."}, {"generated": ["Springer Nature"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["30 min", "520 ppm", "5% ammonia", "180 \u00b5L", "2-4-dibromoacetophenone", "30 seconds"], "gold": [], "text": "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min."}, {"generated": ["morning", "two weeks", "4.5 mg/200 g BW", "single"], "gold": [], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["morning", "two weeks", "4.5 mg/200 g BW", "single"], "gold": [], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["morning", "two weeks", "4.5 mg/200 g BW", "single"], "gold": [], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["morning", "two weeks", "4.5 mg/200 g BW", "single"], "gold": [], "text": "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)"}, {"generated": ["anaesthetized"], "gold": [], "text": "The animals were anaesthetized before blood collection process."}, {"generated": ["1.0 mL"], "gold": [], "text": "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)"}, {"generated": ["precision", "within-run accuracy", "captopril analysis"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["precision", "within-run accuracy", "captopril analysis"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["precision", "within-run accuracy", "captopril analysis"], "gold": [], "text": "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3)."}, {"generated": ["six rats"], "gold": [], "text": "In selectivity testing, six rats plasma was used."}, {"generated": ["captopril", "plasma sulfhydryl groups", "2-4-dibromoacetophenone"], "gold": [], "text": "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups."}, {"generated": ["captopril", "plasma sulfhydryl groups", "2-4-dibromoacetophenone"], "gold": [], "text": "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups."}, {"generated": ["captopril", "plasma sulfhydryl groups", "2-4-dibromoacetophenone"], "gold": [], "text": "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups."}, {"generated": ["basic pH"], "gold": [], "text": "Ammonia was used during derivatization since the reaction is optimal at basic pH."}, {"generated": ["17"], "gold": [], "text": "The reaction was then stopped by adding formic acid [17]."}, {"generated": ["Two weeks", "H. sabdariffa extract", "coadministration", "GSH level", "expression of the PEPT1 transporter"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["Two weeks", "H. sabdariffa extract", "coadministration", "GSH level", "expression of the PEPT1 transporter"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["Two weeks", "H. sabdariffa extract", "coadministration", "GSH level", "expression of the PEPT1 transporter"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["Two weeks", "H. sabdariffa extract", "coadministration", "GSH level", "expression of the PEPT1 transporter"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["Two weeks", "H. sabdariffa extract", "coadministration", "GSH level", "expression of the PEPT1 transporter"], "gold": [], "text": "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter."}, {"generated": ["2016"], "gold": [], "text": "2016; Eng et\u00a0al."}, {"generated": ["2016"], "gold": [], "text": "2016)."}, {"generated": ["laboratory rodent"], "gold": [], "text": "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum."}, {"generated": ["Agilent 1290 series"], "gold": [], "text": "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA)."}, {"generated": ["might occur"], "gold": [], "text": "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered."}, {"generated": ["List of ages found in text"], "gold": [], "text": "(n\u00a0=\u00a06)."}, {"generated": ["anti-diabetic"], "gold": [], "text": "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4)."}, {"generated": ["during the course of his treatment", "probably"], "gold": [], "text": "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment."}, {"generated": ["during the course of his treatment", "probably"], "gold": [], "text": "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment."}, {"generated": ["seven days"], "gold": [], "text": "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["filtered", "previous filtrate"], "gold": [], "text": "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate."}, {"generated": ["adolescents", "elderly"], "gold": [], "text": "3a and b)."}, {"generated": ["adolescents", "elderly"], "gold": [], "text": "3a and b)."}, {"generated": ["0.642min", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["0.642min", "0.482min"], "gold": [], "text": "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin)."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": [], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": [], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": [], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["inflammatory response", "oxidative stress", "liver damage", "diabetes"], "gold": [], "text": "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response."}, {"generated": ["six rats"], "gold": [], "text": "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats."}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["not applicable"], "gold": [], "text": "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig."}, {"generated": ["9"], "gold": [], "text": "9, Table\u00a02)."}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significantly different from normal group", "diabetic control group"], "gold": [], "text": "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001."}, {"generated": ["significant alterations"], "gold": [], "text": "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin."}, {"generated": ["rats"], "gold": [], "text": "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study."}, {"generated": ["plasma sample preparation", "tissue homogenates"], "gold": [], "text": "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process."}, {"generated": ["plasma sample preparation", "tissue homogenates"], "gold": [], "text": "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process."}, {"generated": ["six rats"], "gold": [], "text": "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["4\u20135 h", "0\u20131 h", "3\u20134 h", "6\u20137 h", "1\u20132 h", "5\u20136 h", "2\u20133 h"], "gold": [], "text": "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["0\u20136 h", "6\u201318 h", "18\u201328 h"], "gold": [], "text": "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration."}, {"generated": ["indomethacin-induced gastric injury"], "gold": [], "text": "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert."}, {"generated": ["model group", "S-AOE", "plasma concentration-time curves", "indomethacin", "M-AOE"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["model group", "S-AOE", "plasma concentration-time curves", "indomethacin", "M-AOE"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["model group", "S-AOE", "plasma concentration-time curves", "indomethacin", "M-AOE"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["model group", "S-AOE", "plasma concentration-time curves", "indomethacin", "M-AOE"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["model group", "S-AOE", "plasma concentration-time curves", "indomethacin", "M-AOE"], "gold": [], "text": "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig."}, {"generated": ["age"], "gold": [], "text": "1)."}, {"generated": ["2.5", "1.875", "1.7"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["2.5", "1.875", "1.7"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["2.5", "1.875", "1.7"], "gold": [], "text": "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring."}, {"generated": ["moderate intake", "375 ml", "occasionally"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["moderate intake", "375 ml", "occasionally"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["moderate intake", "375 ml", "occasionally"], "gold": [], "text": "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy."}, {"generated": ["no ages found"], "gold": [], "text": "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.)."}, {"generated": ["daily diet"], "gold": [], "text": "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement."}, {"generated": ["10%"], "gold": [], "text": "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5]."}, {"generated": ["three patients"], "gold": [], "text": "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin."}, {"generated": ["dose dependent manner"], "gold": [], "text": "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner."}, {"generated": ["high relative quantities"], "gold": [], "text": "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16]."}, {"generated": ["44, 45"], "gold": [], "text": "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45]."}, {"generated": ["7.2"], "gold": [], "text": "7.2."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides."}, {"generated": ["15 day"], "gold": [], "text": "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18]."}, {"generated": ["most studies"], "gold": [], "text": "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["ERK pathway", "adipocyte differentiation", "PI3-K/Akt pathway", "hypotensive activity", "anthocyanins", "blood viscosity", "endothelium-derived relaxant pathways", "new vessel formation", "active site", "several potential mechanisms", "reduction of myocardial mass", "ACE inhibition", "cyclooxygenase inhibitory activity", "calcium influx"], "gold": [], "text": "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59]."}, {"generated": ["extremely high doses", "lower doses"], "gold": [], "text": "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses."}, {"generated": ["extremely high doses", "lower doses"], "gold": [], "text": "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses."}, {"generated": ["described entities"], "gold": [], "text": "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects."}, {"generated": ["customers", "early version"], "gold": [], "text": "As a service to our customers we are providing this early version of the manuscript."}, {"generated": ["customers", "early version"], "gold": [], "text": "As a service to our customers we are providing this early version of the manuscript."}, {"generated": ["clinical importance"], "gold": [], "text": "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance."}, {"generated": ["three-fold increase", "clinically-relevant dose"], "gold": [], "text": "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure."}, {"generated": ["three-fold increase", "clinically-relevant dose"], "gold": [], "text": "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure."}, {"generated": ["21"], "gold": [], "text": "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed."}, {"generated": ["adolescents", "elderly", "senior citizens"], "gold": [], "text": "2.1.2."}, {"generated": ["adolescents", "elderly", "senior citizens"], "gold": [], "text": "2.1.2."}, {"generated": ["adolescents", "elderly", "senior citizens"], "gold": [], "text": "2.1.2."}, {"generated": ["in vitro", "potential mechanism\u2010based inhibitors", "human liver microsomes (HLM)"], "gold": [], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": ["in vitro", "potential mechanism\u2010based inhibitors", "human liver microsomes (HLM)"], "gold": [], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": ["in vitro", "potential mechanism\u2010based inhibitors", "human liver microsomes (HLM)"], "gold": [], "text": "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability."}, {"generated": ["cooling block", "Selleckchem, Houston, TX, USA"], "gold": [], "text": "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)."}, {"generated": ["cooling block", "Selleckchem, Houston, TX, USA"], "gold": [], "text": "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA)."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["noncompetitive", "competitive", "mixed-inhibition"], "gold": [], "text": "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered."}, {"generated": ["clinical setting"], "gold": [], "text": "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting."}, {"generated": ["different tissues"], "gold": [], "text": "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues."}, {"generated": ["tissue-to-plasma partition coefficients"], "gold": [], "text": "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients)."}, {"generated": ["three lignans"], "gold": [], "text": "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated."}, {"generated": ["age"], "gold": [], "text": "An external file that holds a picture, illustration, etc."}, {"generated": ["72"], "gold": [], "text": "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction."}, {"generated": ["no ages found in text"], "gold": [], "text": "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates."}, {"generated": ["different cancer cell lines"], "gold": [], "text": "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines."}, {"generated": ["haemorrhage"], "gold": [], "text": "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents."}, {"generated": ["Real Time-Polymerase Chain Reaction", "Western blot"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["Real Time-Polymerase Chain Reaction", "Western blot"], "gold": [], "text": "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM."}, {"generated": ["pharmacodynamic analysis"], "gold": [], "text": "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis)."}, {"generated": ["2005"], "gold": [], "text": "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36]."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["10 min", "30 min", "90 min", "13 min", "12 min", "5 min"], "gold": [], "text": "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection."}, {"generated": ["420%"], "gold": [], "text": "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group."}, {"generated": ["doses of Danshen", "vehicle control group", "mRNA expression level of CYP2C6"], "gold": [], "text": "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group."}, {"generated": ["doses of Danshen", "vehicle control group", "mRNA expression level of CYP2C6"], "gold": [], "text": "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group."}, {"generated": ["doses of Danshen", "vehicle control group", "mRNA expression level of CYP2C6"], "gold": [], "text": "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["P < 0.01", "P < 0.001", "P < 0.05"], "gold": [], "text": "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group."}, {"generated": ["32", "24"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["32", "24"], "gold": [], "text": "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM."}, {"generated": ["previous study", "rats"], "gold": [], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": ["previous study", "rats"], "gold": [], "text": "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32]."}, {"generated": ["taken together with the results of the current study"], "gold": [], "text": "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG."}, {"generated": ["no ages found in text"], "gold": [], "text": "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322]."}, {"generated": ["human", "rats", "several different species"], "gold": [], "text": "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity."}, {"generated": ["human", "rats", "several different species"], "gold": [], "text": "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity."}, {"generated": ["human", "rats", "several different species"], "gold": [], "text": "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity."}, {"generated": ["warfarin dose"], "gold": [], "text": "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54]."}, {"generated": ["57"], "gold": [], "text": "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57]."}, {"generated": ["warfarin hydroxylation"], "gold": [], "text": "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58]."}, {"generated": ["in vitro", "in vivo"], "gold": [], "text": "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results."}, {"generated": ["in vitro", "in vivo"], "gold": [], "text": "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results."}, {"generated": ["no ages found in text"], "gold": [], "text": "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study."}, {"generated": ["early stage breast cancer"], "gold": [], "text": "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer."}, {"generated": ["publication"], "gold": [], "text": "Sample preparation was based on the publication by (Beer et al."}, {"generated": ["88%", "mean recovery"], "gold": [], "text": "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte."}, {"generated": ["88%", "mean recovery"], "gold": [], "text": "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte."}, {"generated": ["interference with drug quantitation", "extracted ion chromatograms"], "gold": [], "text": "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation."}, {"generated": ["interference with drug quantitation", "extracted ion chromatograms"], "gold": [], "text": "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["37 months", "113 months", "4 months"], "gold": [], "text": "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy."}, {"generated": ["Competing interests"], "gold": [], "text": "Competing interests          The authors have declared no conflicts of interests."}, {"generated": ["chronically ill patients", "patients with terminal diseases"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["chronically ill patients", "patients with terminal diseases"], "gold": [], "text": "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["cancer", "peptic ulcer", "diabetes", "antimalarials", "hypertension", "antimicrobials", "chronic diseases", "asthma", "minor ailments"], "gold": [], "text": "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014)."}, {"generated": ["over 70%"], "gold": [], "text": "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014)."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["filtered", "concentrated", "freeze-dried"], "gold": [], "text": "Each mixture was filtered, concentrated, and freeze\u2010dried."}, {"generated": ["Merck", "Darmstadt", "LiChrosolv GG", "Germany"], "gold": [], "text": "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany)."}, {"generated": ["Merck", "Darmstadt", "LiChrosolv GG", "Germany"], "gold": [], "text": "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany)."}, {"generated": ["Merck", "Darmstadt", "LiChrosolv GG", "Germany"], "gold": [], "text": "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany)."}, {"generated": ["Merck", "Darmstadt", "LiChrosolv GG", "Germany"], "gold": [], "text": "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany)."}, {"generated": ["2013", "2005", "2007"], "gold": [], "text": "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013)."}, {"generated": ["2013", "2005", "2007"], "gold": [], "text": "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013)."}, {"generated": ["2013", "2005", "2007"], "gold": [], "text": "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013)."}, {"generated": ["positive ion mode", "Multiple reaction monitoring (MRM) mode"], "gold": [], "text": "Multiple reaction monitoring (MRM) mode using positive ion mode."}, {"generated": ["positive ion mode", "Multiple reaction monitoring (MRM) mode"], "gold": [], "text": "Multiple reaction monitoring (MRM) mode using positive ion mode."}, {"generated": ["concentration of aqueous extract of herb", "Fifty percent inhibitory concentration"], "gold": [], "text": "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations."}, {"generated": ["concentration of aqueous extract of herb", "Fifty percent inhibitory concentration"], "gold": [], "text": "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations."}, {"generated": ["commonly used herbs"], "gold": [], "text": "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013)."}, {"generated": ["three of the plants", "highest dose of the extract", "eight major human CYP isoenzymes"], "gold": [], "text": "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs."}, {"generated": ["three of the plants", "highest dose of the extract", "eight major human CYP isoenzymes"], "gold": [], "text": "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs."}, {"generated": ["three of the plants", "highest dose of the extract", "eight major human CYP isoenzymes"], "gold": [], "text": "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs."}, {"generated": ["oven\u2010dried Allium sativum bulbs"], "gold": [], "text": "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used."}, {"generated": ["Strandell"], "gold": [], "text": "Strandell et\u00a0al."}, {"generated": ["2000"], "gold": [], "text": "(2000)."}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": [], "text": "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb."}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": [], "text": "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb."}, {"generated": ["CYP2C19", "CYP3A4", "CYP1A2"], "gold": [], "text": "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb."}, {"generated": ["menopause"], "gold": [], "text": "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["sexual dysfunction", "cognitive declines", "transition to menopause", "mood disorders", "weight gain", "night sweats", "problematic symptoms", "hot flashes", "sleep disturbances"], "gold": [], "text": "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines."}, {"generated": ["no ages mentioned"], "gold": [], "text": "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder."}, {"generated": ["30 days"], "gold": [], "text": "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation."}, {"generated": ["851", "14 days"], "gold": [], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": ["851", "14 days"], "gold": [], "text": "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups."}, {"generated": ["sequentially numbered"], "gold": [], "text": "Double-blinded treatments were allocated using sequentially numbered drug containers."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["lovastatin", "internal standard", "simvastatin hydroxy acid", "Figure 4", "mean (SD)", "simvastatin", "plasma concentrations"], "gold": [], "text": "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04."}, {"generated": ["mean (SD)"], "gold": [], "text": "Values are expressed as mean (SD)."}, {"generated": ["P < 0.05"], "gold": [], "text": "A difference was considered significant at P < 0.05."}, {"generated": ["40 mg"], "gold": [], "text": "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin."}, {"generated": ["worldwide popularity"], "gold": [], "text": "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability."}, {"generated": ["illnesses"], "gold": [], "text": "Drug interactions can be considered illnesses by themselves."}, {"generated": ["measures", "lifestyle", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["measures", "lifestyle", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["measures", "lifestyle", "possible interactions"], "gold": [], "text": "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software."}, {"generated": ["All subjects"], "gold": [], "text": "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported."}, {"generated": ["n= 12", "2 weeks"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["n= 12", "2 weeks"], "gold": [], "text": "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate."}, {"generated": ["not specified"], "gold": [], "text": "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics."}, {"generated": ["not specified"], "gold": [], "text": "Gorski et al."}, {"generated": ["previous studies"], "gold": [], "text": "The reason for the discrepancy with previous studies remains unclear."}, {"generated": ["health care professionals", "high levels of herb-drug use", "earlier surveys"], "gold": [], "text": "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively)."}, {"generated": ["health care professionals", "high levels of herb-drug use", "earlier surveys"], "gold": [], "text": "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively)."}, {"generated": ["health care professionals", "high levels of herb-drug use", "earlier surveys"], "gold": [], "text": "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively)."}, {"generated": ["herb-drug interactions", "potential", "first stage", "In vitro"], "gold": [], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": ["herb-drug interactions", "potential", "first stage", "In vitro"], "gold": [], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": ["herb-drug interactions", "potential", "first stage", "In vitro"], "gold": [], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": ["herb-drug interactions", "potential", "first stage", "In vitro"], "gold": [], "text": "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions."}, {"generated": ["type 1"], "gold": [], "text": "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["Waters Alliance 2690 HPLC", "Waters LCT Time of Flight Mass Spectrometer", "Mass Lynx V4.1 software", "High resolution LC-MS", "Waters Micromass Ltd.", "HPLC conditions"], "gold": [], "text": "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above."}, {"generated": ["15"], "gold": [], "text": "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6."}, {"generated": ["35"], "gold": [], "text": "[35]."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried)."}, {"generated": ["significantly (p \u2264 0.05)"], "gold": [], "text": "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve."}, {"generated": ["ages found in text"], "gold": [], "text": "An external file that holds a picture, illustration, etc."}, {"generated": ["Five days"], "gold": [], "text": "Five days after presentation, her symptoms had completely resolved."}, {"generated": ["well-studied treatment"], "gold": [], "text": "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion."}, {"generated": ["refractory", "extract"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["refractory", "extract"], "gold": [], "text": "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis."}, {"generated": ["selected single herbs", "Wen Bing formulas"], "gold": [], "text": "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas."}, {"generated": ["selected single herbs", "Wen Bing formulas"], "gold": [], "text": "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas."}, {"generated": ["1902"], "gold": [], "text": "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002."}, {"generated": ["as internal standard"], "gold": [], "text": "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem."}, {"generated": ["8 mg/mL", "600 \u03bcL", "5 \u03bcL"], "gold": [], "text": "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS."}, {"generated": ["8 mg/mL", "600 \u03bcL", "5 \u03bcL"], "gold": [], "text": "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS."}, {"generated": ["8 mg/mL", "600 \u03bcL", "5 \u03bcL"], "gold": [], "text": "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS."}, {"generated": ["30 minutes", "8 PM", "Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 minutes", "8 PM", "Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["30 minutes", "8 PM", "Day 5"], "gold": [], "text": "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity."}, {"generated": ["significantly suppressed", "all the herb/herbal components"], "gold": [], "text": "The formation rate of OSA could be significantly suppressed by all the herb/herbal components."}, {"generated": ["significantly suppressed", "all the herb/herbal components"], "gold": [], "text": "The formation rate of OSA could be significantly suppressed by all the herb/herbal components."}, {"generated": ["teen", "ten marker components"], "gold": [], "text": "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs."}, {"generated": ["teen", "ten marker components"], "gold": [], "text": "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs."}, {"generated": ["anti-influenza herbs/herbal components", "in-vitro experiments"], "gold": [], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": ["anti-influenza herbs/herbal components", "in-vitro experiments"], "gold": [], "text": "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism."}, {"generated": ["decrease", "significantly increase"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["decrease", "significantly increase"], "gold": [], "text": "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["AGE", "oxidative stress", "OSA", "OS ratio", "rat urine samples", "AGEs", "Renal senescence"], "gold": [], "text": "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig."}, {"generated": ["S8"], "gold": [], "text": "S8)."}, {"generated": ["influenza viruses"], "gold": [], "text": "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components."}, {"generated": ["100 \u03bcg/mL", "rat plasma", "500 \u03bcg/mL"], "gold": [], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["100 \u03bcg/mL", "rat plasma", "500 \u03bcg/mL"], "gold": [], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["100 \u03bcg/mL", "rat plasma", "500 \u03bcg/mL"], "gold": [], "text": "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components."}, {"generated": ["rat plasma"], "gold": [], "text": "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Table 1", "absorption rate (k", "pop-PK model", "six-dimension in-vitro screening", "ex-vivo pharmacodynamic evaluation", "after co-administration", "62%", "in-vivo pharmacokinetics in rats", "metabolic clearance (CL"], "gold": [], "text": "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats."}, {"generated": ["Root of Isatis indigotica Fort., Banlangen"], "gold": [], "text": "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)."}, {"generated": ["pre-clinical studies"], "gold": [], "text": "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking."}, {"generated": ["all the cancer patients", "breast cancer patients"], "gold": [], "text": "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010)."}, {"generated": ["all the cancer patients", "breast cancer patients"], "gold": [], "text": "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010)."}, {"generated": ["recent study", "T47D", "TAM", "MCF7"], "gold": [], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": ["recent study", "T47D", "TAM", "MCF7"], "gold": [], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": ["recent study", "T47D", "TAM", "MCF7"], "gold": [], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": ["recent study", "T47D", "TAM", "MCF7"], "gold": [], "text": "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018)."}, {"generated": ["T-47D", "MCF-7"], "gold": [], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": ["T-47D", "MCF-7"], "gold": [], "text": "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010)."}, {"generated": ["many European countries"], "gold": [], "text": "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries."}, {"generated": ["10 Evn-50", "2012"], "gold": [], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": ["10 Evn-50", "2012"], "gold": [], "text": "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012)."}, {"generated": ["12 traditional herbs"], "gold": [], "text": "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010)."}, {"generated": ["2015"], "gold": [], "text": "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["significant increase", "glutathione", "sGPT", "TBARS", "sGOT", "liver transaminases", "TAM-intoxicated liver injury", "antioxidant enzymes", "rats"], "gold": [], "text": "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b)."}, {"generated": ["2009"], "gold": [], "text": "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009)."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["PCA", "MDR1", "in vitro", "GA", "HDI", "BCRP", "OAT1/3"], "gold": [], "text": "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP."}, {"generated": ["2000\u20132019"], "gold": [], "text": "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020)."}, {"generated": ["prostatitis", "pyelonephritis", "urinary tract infections"], "gold": [], "text": "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011)."}, {"generated": ["prostatitis", "pyelonephritis", "urinary tract infections"], "gold": [], "text": "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011)."}, {"generated": ["prostatitis", "pyelonephritis", "urinary tract infections"], "gold": [], "text": "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011)."}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "GA", "tissue distribution-based HDIs", "PCE"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "GA", "tissue distribution-based HDIs", "PCE"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "GA", "tissue distribution-based HDIs", "PCE"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "GA", "tissue distribution-based HDIs", "PCE"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["pharmacokinetic-based HDIs", "PCA", "GA", "tissue distribution-based HDIs", "PCE"], "gold": [], "text": "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies."}, {"generated": ["2006", "1990", "2012", "2007"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["2006", "1990", "2012", "2007"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["2006", "1990", "2012", "2007"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["2006", "1990", "2012", "2007"], "gold": [], "text": "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012)."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["11.5\u201313.5 min", "14\u201315 min", "0\u20138.5 min", "8.7\u201311 min"], "gold": [], "text": "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A."}, {"generated": ["quantification"], "gold": [], "text": "The supernate was utilized for the quantification of GA, PCA, and CIP."}, {"generated": ["318.1", "288.1", "362.2", "332.1"], "gold": [], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": ["318.1", "288.1", "362.2", "332.1"], "gold": [], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": ["318.1", "288.1", "362.2", "332.1"], "gold": [], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": ["318.1", "288.1", "362.2", "332.1"], "gold": [], "text": "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively."}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA", "Figures 3, 4"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA", "Figures 3, 4"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["co-administration of CIP and PCE", "PK changes of GA and PCA", "Figures 3, 4"], "gold": [], "text": "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively."}, {"generated": ["intravenous administration", "intragastric administration"], "gold": [], "text": "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively."}, {"generated": ["intravenous administration", "intragastric administration"], "gold": [], "text": "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively."}, {"generated": ["no ages found in text"], "gold": [], "text": "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively."}, {"generated": ["approximately 1%", "approximately 10%"], "gold": [], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": ["approximately 1%", "approximately 10%"], "gold": [], "text": "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia."}, {"generated": ["2018ZX09734-002", "2021ZD017", "2021ZD030"], "gold": [], "text": "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine."}, {"generated": ["2018ZX09734-002", "2021ZD017", "2021ZD030"], "gold": [], "text": "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine."}, {"generated": ["2018ZX09734-002", "2021ZD017", "2021ZD030"], "gold": [], "text": "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine."}, {"generated": ["not specified"], "gold": [], "text": "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher."}, {"generated": ["laboratory", "similar"], "gold": [], "text": "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity."}, {"generated": ["laboratory", "similar"], "gold": [], "text": "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity."}, {"generated": ["not at all", "extremely"], "gold": [], "text": "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm)."}, {"generated": ["not at all", "extremely"], "gold": [], "text": "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm)."}, {"generated": ["13.3", "15.00"], "gold": [], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": ["13.3", "15.00"], "gold": [], "text": "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001)."}, {"generated": ["exercise time (Figure 3)", "Total Energy Expenditure (TEE)", "treatment (YM vs. PLC)"], "gold": [], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": ["exercise time (Figure 3)", "Total Energy Expenditure (TEE)", "treatment (YM vs. PLC)"], "gold": [], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": ["exercise time (Figure 3)", "Total Energy Expenditure (TEE)", "treatment (YM vs. PLC)"], "gold": [], "text": "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3)."}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["24% increase", "low to moderate exercise intensities"], "gold": [], "text": "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22]."}, {"generated": ["12 weeks"], "gold": [], "text": "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21]."}, {"generated": ["active ingredients", "bioavailability"], "gold": [], "text": "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion."}, {"generated": ["active ingredients", "bioavailability"], "gold": [], "text": "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion."}, {"generated": ["mood state", "satiety", "favorable psychomotor effects"], "gold": [], "text": "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols."}, {"generated": ["mood state", "satiety", "favorable psychomotor effects"], "gold": [], "text": "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols."}, {"generated": ["mood state", "satiety", "favorable psychomotor effects"], "gold": [], "text": "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols."}, {"generated": ["longitudinal YM effectiveness", "future research", "physically active", "lower BF% percentile"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["longitudinal YM effectiveness", "future research", "physically active", "lower BF% percentile"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["longitudinal YM effectiveness", "future research", "physically active", "lower BF% percentile"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["longitudinal YM effectiveness", "future research", "physically active", "lower BF% percentile"], "gold": [], "text": "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment."}, {"generated": ["Seoul, Korea"], "gold": [], "text": "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea)."}, {"generated": ["ad libitum"], "gold": [], "text": "Food and water were supplied ad libitum."}, {"generated": ["Rats"], "gold": [], "text": "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane."}, {"generated": ["various patient demographics"], "gold": [], "text": "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6]."}, {"generated": ["CYP450 family", "DMEs"], "gold": [], "text": "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family."}, {"generated": ["CYP450 family", "DMEs"], "gold": [], "text": "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family."}, {"generated": ["further", "clinical", "anecdotal"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["further", "clinical", "anecdotal"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["further", "clinical", "anecdotal"], "gold": [], "text": "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["memory loss", "cardiovascular disorders", "general well-being", "symptoms of cognition decline", "anxiety and mood disorders", "fatigue", "clinically significant improvement"], "gold": [], "text": "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61]."}, {"generated": ["subtherapeutic"], "gold": [], "text": "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs."}, {"generated": ["human studies", "midazolam"], "gold": [], "text": "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88]."}, {"generated": ["human studies", "midazolam"], "gold": [], "text": "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88]."}, {"generated": ["chronic use", "itself"], "gold": [], "text": "Chronic use of ginseng on its own has been associated with manic psychosis [90]."}, {"generated": ["chronic use", "itself"], "gold": [], "text": "Chronic use of ginseng on its own has been associated with manic psychosis [90]."}, {"generated": ["described entities"], "gold": [], "text": "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits."}, {"generated": ["18"], "gold": [], "text": "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104]."}, {"generated": ["21"], "gold": [], "text": "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate."}, {"generated": ["herbal products"], "gold": [], "text": "This is important because the vast majority of herbal products are orally administered."}, {"generated": ["different herbal species", "many marketed herbal products"], "gold": [], "text": "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood."}, {"generated": ["different herbal species", "many marketed herbal products"], "gold": [], "text": "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood."}, {"generated": ["human small intestinal enterocytes"], "gold": [], "text": "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes."}, {"generated": ["rich sources", "drugs", "natural bioactive compounds"], "gold": [], "text": "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs."}, {"generated": ["rich sources", "drugs", "natural bioactive compounds"], "gold": [], "text": "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs."}, {"generated": ["rich sources", "drugs", "natural bioactive compounds"], "gold": [], "text": "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs."}, {"generated": ["kidney transplantation"], "gold": [], "text": "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation."}, {"generated": ["age found in text"], "gold": [], "text": "This is especially important for drugs with a narrow therapeutic window."}, {"generated": ["April 2016"], "gold": [], "text": "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors."}, {"generated": ["74.27"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["serious adverse effects"], "gold": [], "text": "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects."}, {"generated": ["List of ages found in text"], "gold": [], "text": "Author contributions: MK drafted the initial and final versions of the manuscript."}, {"generated": ["graft rejection"], "gold": [], "text": "Sirolimus is an immunosuppressive drug used to prevent graft rejection."}, {"generated": ["no ages found in text"], "gold": [], "text": "Therapeutic drug monitoring is required as with other immunosuppressive drugs."}, {"generated": ["74.27"], "gold": [], "text": "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable."}, {"generated": ["possible effect"], "gold": [], "text": "In this patient, we reported the possible effect of parsley juice on the level of sirolimus."}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["n = 6", "mean \u00b1 S. D."], "gold": [], "text": "Data are expressed as mean \u00b1 S. D. (n = 6)."}, {"generated": ["statistically significant differences", "groups 2 and 3", "groups 1 and 2"], "gold": [], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": ["statistically significant differences", "groups 2 and 3", "groups 1 and 2"], "gold": [], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": ["statistically significant differences", "groups 2 and 3", "groups 1 and 2"], "gold": [], "text": "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil."}, {"generated": ["Zuccotti Park"], "gold": [], "text": "et Zucc.)"}, {"generated": ["pretreatment period", "possible herbal drug effect"], "gold": [], "text": "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect."}, {"generated": ["pretreatment period", "possible herbal drug effect"], "gold": [], "text": "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect."}, {"generated": ["evaporated", "combined", "dryness"], "gold": [], "text": "The combined extraction solution was then evaporated to dryness."}, {"generated": ["evaporated", "combined", "dryness"], "gold": [], "text": "The combined extraction solution was then evaporated to dryness."}, {"generated": ["evaporated", "combined", "dryness"], "gold": [], "text": "The combined extraction solution was then evaporated to dryness."}, {"generated": ["patients", "elderly", "senior citizens", "available"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["patients", "elderly", "senior citizens", "available"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["patients", "elderly", "senior citizens", "available"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["patients", "elderly", "senior citizens", "available"], "gold": [], "text": "Maxim extract are available from the authors."}, {"generated": ["regulatory environment", "Europe", "practical effects"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["regulatory environment", "Europe", "practical effects"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["regulatory environment", "Europe", "practical effects"], "gold": [], "text": "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13]."}, {"generated": ["less knowledge"], "gold": [], "text": "It most often means that we have less knowledge of benefits, as well as risks."}, {"generated": ["years"], "gold": [], "text": "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years."}, {"generated": ["most frequently occurring species"], "gold": [], "text": "From the combined literature, a list of the most frequently occurring species was established."}, {"generated": ["56.6%"], "gold": [], "text": "They found a prevalence of 56.6%."}, {"generated": ["described in text"], "gold": [], "text": "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34]."}, {"generated": ["two studies"], "gold": [], "text": "Thus, two studies from Canada and the USA were screened to find plants that patients might use."}, {"generated": ["safe daily dose"], "gold": [], "text": "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose."}, {"generated": ["short-term", "time until surgical intervention"], "gold": [], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["short-term", "time until surgical intervention"], "gold": [], "text": "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention."}, {"generated": ["2\u20133 days", "500 mg"], "gold": [], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": ["2\u20133 days", "500 mg"], "gold": [], "text": "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117]."}, {"generated": ["insufficiently defined product quality"], "gold": [], "text": "There are only food supplements available, with insufficiently defined product quality."}, {"generated": ["emerging"], "gold": [], "text": "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases."}, {"generated": ["teenagers", "older adults"], "gold": [], "text": "This is debated, and there are hints to possible beneficial effects [135]."}, {"generated": ["teenagers", "older adults"], "gold": [], "text": "This is debated, and there are hints to possible beneficial effects [135]."}, {"generated": ["154"], "gold": [], "text": "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154]."}, {"generated": ["not specified"], "gold": [], "text": "Seong et al."}, {"generated": ["2018"], "gold": [], "text": "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use."}, {"generated": ["more frequently", "these groups"], "gold": [], "text": "HILI could occur more frequently in these groups because of the combination of risk factors."}, {"generated": ["more frequently", "these groups"], "gold": [], "text": "HILI could occur more frequently in these groups because of the combination of risk factors."}, {"generated": ["3 weeks"], "gold": [], "text": "applied atorvastatin in rats after 3 weeks of drinking green tea or water."}, {"generated": ["unusually susceptible", "individual genotype"], "gold": [], "text": "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207]."}, {"generated": ["unusually susceptible", "individual genotype"], "gold": [], "text": "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207]."}, {"generated": ["human"], "gold": [], "text": "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234]."}, {"generated": ["28%", "7.5", "weekly", "15"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["28%", "7.5", "weekly", "15"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["28%", "7.5", "weekly", "15"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["28%", "7.5", "weekly", "15"], "gold": [], "text": "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability."}, {"generated": ["individual susceptibility"], "gold": [], "text": "The clinical significance of this phenomenon depends on individual susceptibility."}, {"generated": ["great proportion"], "gold": [], "text": "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7]."}, {"generated": ["published maps", "institutional affiliations"], "gold": [], "text": "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["published maps", "institutional affiliations"], "gold": [], "text": "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["variety of ages found in text"], "gold": [], "text": "Diabetes is a complex condition with a variety of causes and pathophysiologies."}, {"generated": ["not applicable"], "gold": [], "text": "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules."}, {"generated": ["HDI", "pharmacodynamic"], "gold": [], "text": "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur."}, {"generated": ["HDI", "pharmacodynamic"], "gold": [], "text": "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur."}, {"generated": ["large number of sulfur compounds", "allyl thiosulfinates", "bioactive compounds", "allyl thiosulfinates (mainly allicin)"], "gold": [], "text": "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65]."}, {"generated": ["large number of sulfur compounds", "allyl thiosulfinates", "bioactive compounds", "allyl thiosulfinates (mainly allicin)"], "gold": [], "text": "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65]."}, {"generated": ["large number of sulfur compounds", "allyl thiosulfinates", "bioactive compounds", "allyl thiosulfinates (mainly allicin)"], "gold": [], "text": "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65]."}, {"generated": ["large number of sulfur compounds", "allyl thiosulfinates", "bioactive compounds", "allyl thiosulfinates (mainly allicin)"], "gold": [], "text": "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65]."}, {"generated": ["two millennia"], "gold": [], "text": "This herb has been in use for diabetic treatment for almost two millennia [72]."}, {"generated": ["individuals with diabetes"], "gold": [], "text": "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels."}, {"generated": ["experimental"], "gold": [], "text": "Evidence supporting the interaction between Lycium and antidiabetics is experimental only."}, {"generated": ["conventional antidiabetics"], "gold": [], "text": "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86]."}, {"generated": ["98"], "gold": [], "text": "no interaction [98]."}, {"generated": ["relevant chemical and pharmacological data", "complex herbal interventions", "more complex interactions"], "gold": [], "text": "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions."}, {"generated": ["relevant chemical and pharmacological data", "complex herbal interventions", "more complex interactions"], "gold": [], "text": "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions."}, {"generated": ["relevant chemical and pharmacological data", "complex herbal interventions", "more complex interactions"], "gold": [], "text": "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions."}, {"generated": ["no ages found in text"], "gold": [], "text": "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions."}, {"generated": ["Springer Nature"], "gold": [], "text": "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."}, {"generated": ["various ages found in text"], "gold": [], "text": "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999)."}, {"generated": ["several studies"], "gold": [], "text": "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996)."}, {"generated": ["USP reference standard"], "gold": [], "text": "The internal standards codeine and betaxolol were of USP reference standard."}, {"generated": ["HPLC grade solvents", "General-purpose reagents", "HPLC determinations"], "gold": [], "text": "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations."}, {"generated": ["HPLC grade solvents", "General-purpose reagents", "HPLC determinations"], "gold": [], "text": "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations."}, {"generated": ["HPLC grade solvents", "General-purpose reagents", "HPLC determinations"], "gold": [], "text": "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations."}, {"generated": ["significant P value \u2a7d0.05"], "gold": [], "text": "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05."}, {"generated": ["in vitro", "concentration dependent manner"], "gold": [], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}, {"generated": ["in vitro", "concentration dependent manner"], "gold": [], "text": "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig."}, {"generated": ["25 \u03bcg/ml"], "gold": [], "text": "The activation was highest at 25\u00a0\u03bcg/ml concentration."}, {"generated": ["healthy human volunteers"], "gold": [], "text": "The in vivo study was conducted on healthy human volunteers."}, {"generated": ["clinical study"], "gold": [], "text": "Therefore, the clinical study was conducted to confirm the in vitro results."}, {"generated": ["abemaciclib-related diarrhea", "quality of life", "patients' outcomes"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["abemaciclib-related diarrhea", "quality of life", "patients' outcomes"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}, {"generated": ["abemaciclib-related diarrhea", "quality of life", "patients' outcomes"], "gold": [], "text": "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life."}], "FN": [{"generated": ["middle-aged (50\u201364)"], "gold": ["50\u201364"], "text": "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups."}]}